Archives: Premium Distribution

October 25, 2022 10:35:46

Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million through the sale of one million shares of common stock,” reads a recent article. “Originally founded in 2010, Silo Pharma has distinguished itself amongst peers for its ground-breaking research into conditions such as post-traumatic stress disorder (‘PTSD’), fibromyalgia, Alzheimer’s, Parkinson’s, and other rare neurological disorders. Increasingly and over the past two decades, clinical research on psychedelics, most notably psilocybin and methylenedioxymethamphetamine (‘MDMA’), has steadily progressed from pilot studies confirming safety and feasibility through to early phase trials providing preliminary evidence of clinical efficacy. Silo Pharma has been an early pioneer of these research studies through its commitment to developing innovative solutions to address a variety of underserved conditions, many of which are being carried out in partnership with leading medical universities across the globe.”

To view the full article, visit https://ibn.fm/IWQM6

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

BiondVax Pharmaceuticals (NASDAQ: BVXV) to Present at LD Micro Main Event XV

October 25, 2022 10:35:14

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses, has announced that its Director of Investor Relations, Joshua Phillipson, will attend and present at the LD Micro Main Event XV. The leading small cap investor conference is taking place in Los Angeles on Oct. 25 to 27, 2022, and will showcase more than 200 companies. Phillipson is scheduled to present at 9 a.m. PT on Tuesday, Oct. 25, in Track 3, and will discuss BiondVax’s investment case, including its highly experienced leadership team, innovative nanosized antibody (“NanoAb”) platform, the company’s derisked pipeline development, in-house GMP biologics manufacturing facility, and key upcoming milestones. He will also be available for one-on-one meetings with investors throughout the conference. Interested parties should visit https://ibn.fm/HBhgV to register for the event.

To view the full press release, visit https://ibn.fm/dDLRU

About BiondVax Pharmaceuticals Ltd.

BiondVax is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. Since its inception, BiondVax has executed eight clinical trials including a seven country, 12,400 participant phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

DoubleDown Interactive (NASDAQ: DDI) Announces Q3 Earnings Call

October 25, 2022 10:34:49

DoubleDown Interactive (NASDAQ: DDI), a leading gaming company that delivers unique player experiences across a variety of genres, has scheduled a conference call for Nov. 8, 2022, at 5 p.m. ET. DDI management will host the call and discuss the company’s financial and corporate results for the third quarter, the period ending Sept. 30, 2022. According to the announcement, the company will release its financial results prior to the call. During the call, DDI leaders will offer a presentation; the call will also include a Q&A session. Interested participants can register to attend the call and, after registering, will receive an email with information about dialing into the call, along with an access code. A simultaneous webcast of the conference call will also be available. Following the call, a replay of the event will be available on the company’s investor relations website.

To view the call, visit https://ibn.fm/4aVRq or https://ibn.fm/WgVND

To view the full press release, visit https://ibn.fm/BUj71

About DoubleDown Interactive Co. Ltd.

DoubleDown Interactive is a leading developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multiformat interactive entertainment experiences for casual players, bringing authentic Vegas entertainment to players around the world through an online social casino experience. DDI’s flagship title, DoubleDown Casino, has been a fan-favorite game on leading social and mobile platforms for years, entertaining millions of players worldwide with a lineup of classic and modern games. For more information about the company, visit www.DoubleDownInteractive.com.

About InvestorWire

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Announces Webcast to Discuss M&A, International Markets

October 25, 2022 10:34:13

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has scheduled an analyst call for Oct. 26, 2022, at 2 p.m. EST. According to the announcement, the call will focus on the company’s recent M&A activity as well as growth opportunities in the international space. Leadership from Flora Growth, along with Franchise Global Health Inc., will be on the call to discuss the recent definitive agreement that two companies have signed regarding acquisition; discussion will also center on global opportunities within the cannabis industry. Through its subsidiaries, Franchise Global Health is a multinational operator in the medical cannabis and pharmaceutical industries, with principal operations in Germany along with operations, assets, strategic partnerships and investments internationally. Flora Growth encourages analysts to attend the conference call or live webcast, which will also include a Q&A session. A replay of the event will be available on the company’s website following the call.

To access the event, visit https://cnw.fm/mBies

To view the full press release, visit https://cnw.fm/EHA7B

About Flora Growth Corp.

Flora Growth is building a connected, design-led collective of plant-based wellness and lifestyle brands designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Golden Matrix (NASDAQ: GMGI) Continually Upgrading Systems, Content to Maintain Competitive Edge

October 24, 2022 11:20:48

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, is leveraging the growth opportunity that has arisen as casino operators embrace digital avenues. “Golden Matrix’s GM-AG System is the industry standard for gaming platforms, including leading graphics and over 10,000 games to give casino operators a copious number of options and management software to keep customers happy and loyal to their brand. As a rule, casinos can’t have enough online table games, which is right in GMGI’s wheelhouse… Golden Matrix is only scratching the surface of the bounds of its potential domain. Most of its business has historically been business-to-business with operators focused in Asia-Pacific. Last year, the company bought 80% of RKings Competition Ltd., marking its entrance into the European markets, as well as the business-to-consumer segment. The company is amid its next expansion move, which will bring RKings’ competitions to the Mexican markets,” a recent article reads. “Because of the highly competitive nature of our industry, we are continually upgrading our systems and gaming content to support the needs of our millions of participants,” Golden Matrix CEO Anthony Brian Goodman is quoted as saying.

To view the full article, visit https://ibn.fm/QtLzr

About Golden Matrix Group Inc.

Golden Matrix Group, based in Las Vegas, Nevada, is an established gaming technology company that develops and owns online gaming IP and builds configurable and scalable white-label B2B gaming platforms for its international customers, located primarily in the Asia Pacific region. The gaming IP includes tools for marketing, acquisition, retention and monetization of users. The company’s platform can be accessed through both desktop and mobile applications. As a result of its 80% controlling ownership interest in U.K.-based RKings Competitions Ltd., Golden Matrix also generates revenues from RKings’ scalable B2C tournament platform. Its sophisticated software automatically declines any gaming or redemption requests from within the United States, in strict compliance with current U.S. law. For more information about the company, visit www.GoldenMatrix.com.

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

HeartBeam’s (NASDAQ: BEAT) Patented Tech Poised to Disrupt ECG Patch Market

October 24, 2022 11:20:13

HeartBeam (NASDAQ: BEAT) recently received a patent from the United States Patent and Trademark Office for its 12-lead electrocardiogram (“ECG”) patch monitor for the detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia. “The new patent expands on a previously granted patent for a 12-lead ECG patch monitor technology. HeartBeam noted that the patent opens a pathway to a disruptive ischemia and arrhythmia detection ECG patch product. In addition, the innovation builds on HeartBeam’s growing intellectual property portfolio that could enable 12-lead ECG diagnostics outside of a medical setting… Currently, the ECG patch monitor market is limited to detecting arrhythmias using single-lead ECG devices. HeartBeam’s technology uses a synthesized 12-lead ECG that can aid physicians in both arrhythmia detection and ACS diagnosis, including myocardial infarction (heart attack) and angina. According to the company, the new patent follows HeartBeam’s already-granted core patents for remote detection of heart attacks,” a recent article reads. “Our 12-lead ECG patch technology offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care and could have a disruptive effect on the ECG patch market with its ischemia detection capability,” HeartBeam CEO and founder Branislav Vajdic, PhD, was quoted as saying.

To view the full article, visit https://ibn.fm/oqhTV

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine if symptoms are due to a heart attack, quickly and easily, so care can be expedited, if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo(TM) is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (“FDA”) for marketing in the USA or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) Holds Potential for Multiple Commercial Opportunities

October 24, 2022 11:19:35

Lexaria Bioscience Corp. (NASDAQ: LEXX), a drug delivery platform innovator, last year announced a review of its successful 2021 antiviral drug program. “Lexaria specifically probed the bioavailability of five DehydraTECH(TM)-processed antiviral drugs for SARS-CoV-2, HIV/AIDS and other infectious diseases from three drug classes, evidencing significant gains with up to a three-fold increase in oral drug delivery into the bloodstream. The demonstrated improvements in absorption, Lexaria believed, could have significant commercial potential considering that many antiviral drugs typically show low oral bioavailability in their available form because of significant liver biotransformation and/or poor intestinal uptake,” reads a recent article. “Lexaria’s vision for DehydraTECH is not limited to antiviral drugs as the company is also focusing on other possible mainstream applications of its disruptive drug delivery platform, including but not limited to oral nicotine and cannabidiol (‘CBD’). Pharmacokinetic studies evaluating these compounds have, in fact, shown that DehydraTECH delivers higher quantities of these APIs in less time… DehydraTECH’s ability to increase the performance of different APIs represents multiple commercial opportunities that, when tapped, could potentially address serious unmet patient needs.”

To view the full article, visit https://cnw.fm/8Mnlp

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 27 patents granted and roughly 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Enters Acquisition Agreement with German Cannabis Distributor

October 24, 2022 11:18:47

Flora Growth (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has inked a definitive agreement with Franchise Global Health Inc. (TSX.V: FGH), a multinational operator in the medical cannabis and pharmaceutical industry. The agreement outlines Flora Growth’s plans to acquire 100% of Franchise Global Health, which has principal operations in Germany, in an all-stock transaction. According to the agreement, the acquisition gives FLGC a foothold in German’s medical cannabis space because FGH’s German businesses service an estimated 1,200 pharmacies in the country; FGH also provides noncannabis medical products to 28 additional countries. In the first six months of this year, FGH reported revenue of approximately C$30.1 million; total aggregated reported revenues for both companies for the period ended June 30, 2022, reached $38.6 million. The agreement calls for Flora Growth’s indirect acquisition of FGH’s subsidiaries, including Phatebo GmbH, a leading distributor of export pharmaceuticals and medical cannabis products to the European Union, and ACA Müller ADAG Pharma Vertriebs GmbH, which holds the first German medical cannabis import and distribution license ever granted. “Through this proposed acquisition, we are connecting our commercial infrastructure and medical cannabis product portfolio to the German and EU medical markets, while gaining direct access to European pharmaceutical distributions,” said Flora Growth chair and CEO Luis Merchan in the press release. “We believe Franchise will significantly increase our commercial international revenue and provide essential distribution to German pharmacies and a growing wholesale market.”

To view the full press release, visit https://cnw.fm/Hjoj7

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands that delivers the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands, and life sciences divisions. For more information about the company, please visit www.FloraGrowth.ca.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Cerberus Sentinel (NASDAQ: CISO) Featured in Equity Research Report

October 24, 2022 11:17:32

Cerberus Sentinel (NASDAQ: CISO), an industry leader as a managed cybersecurity and compliance provider based in Scottsdale, Arizona, was featured in a recent equity research report published by Cantor Fitzgerald titled “Strong Vision and M&A Execution Playbook Position to Address Cyberattacks, Cybersecurity Talent Shortages; Launching Coverage at OW with a $5 PT.” The publication reads, “Growth Strategy Focused on Acquisitions and Organic Expansion. Cerberus Sentinel intends to capitalize on the growing ‘achievement gap’ between increased risk and exposure to cyber threats and the decreasing pool of resources available to address this risk as its core growth opportunity. The majority of the company’s revenue is generated from managed services and, to a lesser extent, professional services. We believe CISO has built a strong, repeatable acquisition strategy aimed at engineer-operated cybersecurity firms in the $2-25 million revenue range with each deal expected to be accretive. We believe these up/cross-sell opportunities should drive sustainable organic growth in the 15-20% range with broaden service offerings upholding the organic cross-sell funnel.”

To view the full report, visit https://ibn.fm/uY8wT

About Cerberus Cyber Sentinel Corporation

Cerberus Sentinel is an industry leader as a managed cybersecurity and compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and compliance obligations. For more information about the company, visit www.CerberusSentinel.com.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Mullen (NASDAQ: MULN) Announces I-GO(TM), a Fully EU Homologated Vehicle

October 24, 2022 11:16:47

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it has secured exclusive sales, distribution and branding rights to the new compact urban delivery electric vehicle, the I-GO, which is fully EU Standard homologated and certified for sale in select European markets. The I-GO bridges the gap between the growing demand for quick deliveries and space constraints found throughout the dense cities of Europe. “Securing the exclusive sales, distribution and branding rights in major European countries for a ready to market electric commercial delivery vehicle is a huge win for the company. The company plans on licensing its rights to established dealerships in these desirable European markets. Essentially, this transaction provides the company revenue generating opportunities, promotes and extends the company’s brand into other countries while at the same time allowing the company to remain fully focused on its mission of manufacturing its lineup of electric vehicles in the USA,” said David Michery, CEO and chairman of Mullen Automotive. “The goal has always been for Mullen to build a complete line of commercial electric vehicles, and we realized that one of the most critical issues today is inefficient last-mile delivery in urban markets. The introduction of the I-GO, a fully EU homologated vehicle, creates opportunities for the company in Europe where there is a huge demand for this type of small delivery vehicle.”

To view the full news release, visit https://ibn.fm/vpQ3A

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of premium electric vehicles (“EVs”) that are affordable and built entirely in the United States. With an end-to-end ecosystem that supports owners from test driving to financing and servicing through a unique hybrid dealership model, customers are supported through every aspect of EV ownership. The Mullen FIVE, the company’s first electric crossover, is slated for delivery in 2024 and features an award-winning design and its patented PERSONA technology that utilizes facial recognition to personalize the driving experience for every individual. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Silo Pharma (NASDAQ: SILO) Announces Data from Dosing Study of SPC-14 for Alzheimer’s

October 20, 2022 10:58:22

Silo Pharma Inc. (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer’s disease (AD), as demonstrated in a mouse model. The research was conducted as part of a sponsored research agreement with Columbia University in New York.

SPC-14, a novel drug that combines an FDA-approved therapeutic with ketamine, is in development for the treatment of dementia related to Alzheimer’s disease. Initial data from its SPC-14 research studies shows that chronic dosing of SPC-14 resulted in increased memory in AD mice and had no negative weight effects on the subjects.

To view the full press release, visit https://ibn.fm/C4Fa1

About Silo Pharma

Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as Alzheimer’s, PTSD, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Lexaria (NASDAQ: LEXX) Using DehydraTECH(TM) to Address Antihypertension Drug Market

October 20, 2022 10:48:15

Research has shown that co-occurring conditions may be linked to high blood pressure, including bone aging and mental illness
The antihypertension drug market is anticipated to rise due to the launch of novel pharmaceuticals and diagnostic agents
Valued at US $30.2 billion in 2021, the market is expected to grow at a CAGR of 3%, resulting in a value of US $40 billion by 2031
Lexaria’s patented DehydraTECH(TM) technology offers higher bioavailability of active pharmaceutical ingredients due to, in part, bypassing first-pass-liver processing, improving the speed of onset, and brain absorption

The American Heart Association (“AMA”) refers to high blood pressure, or hypertension, as a “silent killer.” Nearly half of American adults have hypertension but do not know it because there are no obvious symptoms correlating to the condition. However, research finds that co-occurring conditions may be linked to high blood pressure, including bone aging and mental illness.

A recent study conducted by the AMA has found that hypertension may be linked to significant bone loss. The bone quality in younger mice with hypertension was similar to the bones of older mice without hypertension present. The study suggests that the effects of hypertension on the bones may mimic…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About HempWire

HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.

To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.HempWire.com

Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published: https://www.HempWire.com/Disclaimer

Do you have a questions or are you interested in working with HW? Ask our Editor

HempWire (HW)
Denver, Colorado
www.HempWire.com
303.498.7722 Office
[email protected]

HempWire is part of the InvestorBrandNetwork.

Mullen Automotive (NASDAQ: MULN) Receives Approval to Proceed with ELSM Acquisition

October 20, 2022 10:47:29

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has received approval from the U.S. Bankruptcy Court to move forward on its acquisition of Electric Last Mile Solutions (“ELMS”) assets; ELSM is an electric vehicle company. According to the announcement, the Chapter 7-approved transaction paves the way for Mullen to acquire ELMS’s manufacturing plant along with all inventory and intellectual property. The acquisition will be an all-cash purchase; the company’s cash on hand and a funding commitment of up to $240 million provides the funds to finalize the acquisition and move forward with vehicle launches. The company noted that the factory, which is located in Mishawaka, Indiana, has the capacity to produce up to 50,000 vehicles every year, allowing MULN to accelerate its planned vehicle production for the Mullen FIVE and Bollinger B1, B2 retail vehicles by more than 12 months. In addition, the platform and plant acquisition will result in a significant reduction in the company’s previously forecast overall spend. “Mullen’s acquisition of Bollinger was one of the largest transactions of its kind in the EV market,” said Mullen Automotive CEO and chair David Michery in the press release. “Upon closing the ELMS transaction, the company will be in a position to strategically leverage all its acquired assets to shorten its production path and aggressively expand into the commercial and consumer EV market.”

To view the full article, visit https://ibn.fm/fqbzs

About Mullen Automotive Inc.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Anticipates Leadership in Alternative Cannabinoid Segment

October 20, 2022 10:45:47

Flora Growth Corp. (NASDAQ: FLGC), a global cannabis cultivator, product manufacturer and distributor, is measuring its success in rapidly rising revenues brought on by strategic acquisitions and the expanding international movement of its brands. “The company recently reported a 604% increase YoY in its H1 revenues to about $15 million, which was also a 117% increase over the previous half-year financial report, and is anticipating new momentum from the recent acquisition of the No Cap Hemp Co. brand by Flora’s wholly owned subsidiary Just Brands LLC. The No Cap acquisition is expected to add some 75 SKUs to Flora’s product portfolio plus the ‘No Cap’ and ‘Moonblunt’ trademarks… Flora Growth Chairman and CEO Luis Merchan anticipates that the acquisition of No Cap’s brands will ultimately position Flora as the leader in the alternative cannabinoid market segment and that No Cap’s infusion technology will boost Flora Labs’ manufacturing capabilities,” a recent article reads. “This transaction will allow Flora to immediately benefit from a profitable, cash flow positive and growing business. We look forward to increasing our product offering through this transaction while broadening our sales team in the process,” Merchan is quoted as saying.

To view the full article, visit https://cnw.fm/X0bj7

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands, designed to deliver the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions. Visit www.FloraGrowth.com or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Silo Pharma (NASDAQ: SILO) Enters Agreement with Columbia University to Extend Research Pact

October 19, 2022

October 19, 2022 09:39:28

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into an agreement with Columbia University to extend its current research partnership efforts. The agreement outlines certain assets that are currently under development regarding the work of associate professor of clinical Neurobiology Dr. Christine Ann Denny at Columbia University Irving Medical Center. Denny and her team are studying the molecular mechanisms underlying learning and memory, including diseases such as Alzheimer’s disease. According to the announcement, Denny’s pioneering research is evaluating whether ketamine and novel inventions associated with the substance have potential to improve memory retrieval as well as halt or even reverse the process of memory loss and cognitive aging related to Alzheimer’s. “The first steps of our research with Columbia have been positive, and we’re happy to extend this research and option pact to continue the progress of SPC-14 as an Alzheimer’s therapeutic and SPC-15 for stress-induced anxiety disorders,” said Silo Pharma CEO Eric Weisblum in the press release.

To view the full press release, visit https://ibn.fm/RgX6q

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications such as Alzheimer’s, PTSD and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health-care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Cepton (NASDAQ: CPTN) Schedules Release of Q3 2022 Results, Conference Call

October 19, 2022

October 19, 2022 09:37:51

Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, has announced that it will provide a business update and release its financial results for the third quarter of 2022 following the close of the market on Tuesday, Nov. 8, 2022. In addition, Cepton will hold a conference call and webcast at 2:30 p.m. PT (5:30 p.m. ET) that same day. Interested parties may join the call by dialing 888-999-6281 and visiting https://ibn.fm/01a5B for the live webcast. A replay will be available approximately two hours after the live call and until Nov. 22, 2022, and can be accessed by dialing 844-512-2921 and entering passcode 3684645. An archived webcast of the conference call will be accessible on Cepton’s Investor Relations page.

To view the full press release, visit https://ibn.fm/lywDQ

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors business. Cepton is also engaged with all other top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the Metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information, visit the company’s website at www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) Innovative Robot Roadshow Makes Stop in Dallas

October 19, 2022

October 19, 2022 09:37:31

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”), and its Robot Roadshow are spending the day in Dallas. The roadshow is a free, engaging experiential event that is designed to provide potential clients, media and investors with an opportunity to see Knightscope’s game-changing security robots up close and personal. The stop in Dallas is at the Commemorative Air Force location from 10 a.m. to 3 p.m. CT.

Knightscope is committed to share its offerings through creative marketing events, and the roadshow is an ideal example of this. So far, the event has landed in 64 different locations across 23 states and the District of Columbia. The robots tour the U.S. in what the company describes as a space-age, NASA-like pod, allowing attendees to experience all the technology that is enabling these autonomous security robots to help make sites safer today from Hawaii to Texas to North Carolina. At each stop, Knightscope experts guide visitors through direct interaction with ASRs and provide an opportunity to see the Knightscope Security Operations Center user interface in action.

To view the full press release, visit https://ibn.fm/Tw89x

About Knightscope Inc.

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. The company’s long-term ambition is to make the United States of America the safest country in the world. For more information about the company, please visit www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knight are available in the company’s newsroom at https://ibn.fm/Knight

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Golden Matrix Group (NASDAQ: GMGI) Thrives in an Industry Where Content is King

October 18, 2022 10:19:03

Google recently announced the closure of its Google Stadia gaming business, a decision which may have partly been underpinned by the dearth of new gaming titles available on the platform
Content has remained a crucial driver of success within the iGaming industry, a factor which Golden Matrix Group have sought to cater to
Through their proprietary GM-X turnkey solution, the company provides its licensing partners with access to upward of 10,000 games drawn from over 25 gaming studios

On November 19, 2019, Google made an announcement that was set to potentially change the face of the gaming universe as we know it. Google was set to launch their Google Stadia cloud-based gaming platform, a revolutionary system which bypassed the erstwhile console gaming industry, rather allowing gamers to access their games via streaming across a host of compatible TVs, computers, and mobile devices. However, and whilst the idea was game changing in nature, the execution lagged far behind. Google Stadia recently announced that it would officially shut up shop on January 18, 2023, bringing a close to the internet giant’s push into online gaming (https://ibn.fm/7Z90p). However, a key rationale which may have led to the early closure of Google Stadia may also be the same factor dictating the potential failure or success of the iGaming business – content.

A key issue pinpointed as the reason behind Google Stadia’s relative lack of success was the gaming company’s economic model: subscribers to Stadia Pro would be given a handful of games each month that they could access for as long as they had a subscription – similar to PlayStation Plus – whereas the…

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems Los Angeles, California www.TinyGems.net 310.299.1717 Office [email protected]

TinyGems is part of the InvestorBrandNetwork

Cepton Technologies (NASDAQ: CPTN) Partners with LidarSwiss to Create Nano P60 System

October 18, 2022 10:18:35

Cepton Technologies (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, announced that LidarSwiss Solutions GmbH is deploying its Sora(TM) lidar technology in the company’s drone-based mapping and analytics solution, which is available for infrastructure management and engineering design applications. The full Nano P60 system is on display at the INTERGEO event, held Oct. 18–20, 2022, in Germany. Based in Switzerland, LidarSwiss provides high-performance unmanned aerial vehicle (“UAV”)-based lidar solutions that feature high-fidelity mapping and real-time processing, a key solution for engineers, forestry managers and urban planners. The Nano P60 platform has been used to map and analyze flood plains, highways, power lines and areas for site development in more than 20 cities in Asia, Europe and Australia. “We are proud to be supporting LidarSwiss and its customers with our lidar technology to unlock applications such as 3D modeling for BIM, historical site mapping, terrain modeling for heavy vegetation areas, volumetric calculations for mining, power line inspection and forestry mapping,” said Cepton Technologies director of product management and marketing Klaus Wagner in the press release. “Our Sora lidar is a one-of-a-kind line scanner that combines high frame rate and long range. Powered by Cepton’s proprietary lidar technologies, it is compact, lightweight and rotation free, making it ideal for small UAV applications.”

To view the full press release, visit https://ibn.fm/EOCcy

About Cepton Technologies Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors business. Cepton is also engaged with all other top-10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information about the company, visit www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

CNS Pharmaceuticals (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate

October 18, 2022 10:18:16

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is currently conducting a potentially pivotal global phase 2 clinical trial in humans to test the effectiveness of its anti-glioblastoma (“GBM”) drug candidate – Berubicin. Testing of Berubicin resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by the drug’s original developer over 15 years ago. In its annual stockholder meeting, the company also provided an update for its secondary drug portfolio WP1244. The anthracycline-based substance, being evaluated for the treatment of brain cancers, ovarian and lymphomas, “has produced a new derivative as WP1874 with enhanced solubility compared to WP1244,” a recent article reads. “‘Going forward, WP1874 will be the primary focus in our development efforts of the WP1244 portfolio,’ the company stated… CNS anticipates filing for Investigational New Drug (‘IND’) recognition for WP1874 in the coming year. Berubicin has already been granted Fast Track and Orphan Drug designations by the U.S. Food and Drug Administration (‘FDA’).”

To view the full article, visit https://ibn.fm/6WQtE

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of the WP1244 portfolio in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cybin (NYSE American: CYBN) (NEO: CYBN) Working to Create the Best Psychedelic Therapies for Patients

October 18, 2022 10:17:42

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is conducting a phase 1/2a trial evaluating CYB003, its lead investigational molecule and the first-ever novel psilocybin analog to enter clinical development. “The in-human trial is critical to the company’s continued development of CYB003, a deuterated psilocybin analog that Cybin believes has potential to successfully address the challenges and limitations of oral psilocybin. According to the company’s preclinical research, CYB003 achieved less variability in plasma levels, along with faster onset of action, improved brain penetration, and shorter duration of effect, compared to oral psilocybin. CYB003 has the potential to reduce time in the clinic, which could allow more scalability and access for this treatment. As a randomized, double-blind, placebo-controlled study, the current phase 1/2a trial will evaluate individuals with moderate to severe major depressive disorder (‘MDD’),” a recent article reads. “To commence dosing in our first in-human phase 1/2a trial is a tremendous milestone for Cybin, especially having reached the clinic within just 18 months. Our goal continues to focus on becoming a leader in creating the best psychedelic therapies for patients, and today we have moved one step closer,” Cybin CEO Doug Drysdale is quoted as saying.

To view the full article, visit https://ibn.fm/RLpCI

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Featured in BioWorld(TM) MedTech Article

October 18, 2022 10:16:57

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed an innovative platform for heart attack detection anytime, anywhere, was featured in a recent BioWorld(TM) MedTech article. “HeartBeam Inc. has been awarded a patent for what it called ‘the first and only’ 3D-vector, 12-lead ECG platform for heart attack detection, this in conjunction with a credit card-sized device inside a consumer’s wallet for personal monitoring,” the piece reads. “The company said it can record and remotely transmit a set of cardiac signals to a physician for review so that patients at high risk of cardiac arrest are not left alone deciding if an ER visit is warranted.”

To view the full article, visit https://ibn.fm/vomnh

About HeartBeam Inc.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Changing Landscape for Cannabis Portends Era of Productivity for Flora Growth (NASDAQ: FLGC)

October 17, 2022

October 17, 2022 09:22:03

Colombia and the United States have both recently exhibited new openness to the possibility of decriminalizing adult recreational cannabis use through legislative change
Cannabis supplier Flora Growth cultivates its product at a key Colombian farm and provides it to international markets, and may see additional opportunities arise as cannabis policies advance in the two countries
Flora Growth recently announced completion of its first shipments of high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate supplied to its market in the United States
The company also recently reported a 604 percent YOY increase in revenues during the H1 reporting period, with a 547 percent gross profit increase during that period

Cannabis may be approaching a new watershed moment as Colombia pushes for national legalization of adult-use marijuana and the United States’ government undertakes long-anticipated discussion of whether to change the drug’s classification.

The nearly unanimous approval of legislation to legalize and regulate adult-use cannabis by an initial committee reviewing bills in Colombia’s legislature, coupled with the president’s criticisms of decades-long prohibitionist policies and regulatory advances made by his predecessor, position the fertile…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Freight Technologies (NASDAQ: FRGT) Continues to Broaden Reach with Fr8App B2B Marketplace

October 17, 2022

October 17, 2022 09:21:13

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), an over-the-road shipping technology innovator, has developed an AI-powered marketplace solution for optimizing and automating the supply chain process to help keep trucks moving with minimal obstacles. “The company’s Fr8App B2B marketplace is its flagship product in a suite powered by AI and machine learning technology that helps connect shippers with qualified carriers as a real-time broker portal… In the company’s Q2 2022 financial report, Fr8Tech noted that quarterly revenue for the period ended June 30 grew 60% over the Q1 report and was up 45% for the period YoY, establishing a new record for the company,” a recent article reads. “The growth reflects greater traction in each of our dedicated capacity product, Fr8Fleet, and our U.S. domestic Fr8App services… Fr8App offers many advantages, including time and cost savings, that benefit shippers and carriers. Even when macro-economic challenges persist, goods still need to be delivered in a timely and costly manner, and Fr8App makes the whole process easier. As such, we continue to broaden our customer reach,” Fr8Tech CEO Javier Selgas is quoted as saying.

To view the full article, visit https://ibn.fm/JoTuz

About Freight Technologies Inc.

Freight Technologies is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary Freight App Inc. (“Fr8App”) is a B2B cross-border shipping marketplace in the NAFTA region powered by AI and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions. The company is headquartered in Houston, Texas. For more information, visit the company’s website at Fr8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Lexaria’s (NASDAQ: LEXX) Development Program Seeking to Provide Effective Antihypertensive Medication

October 17, 2022

October 17, 2022 09:20:45

Lexaria Bioscience, a global innovator in drug delivery technology, has developed a potential treatment for hypertension using the company’s patented DehydraTECH(TM) platform, now shown in several human studies to reduce blood pressure and arterial stiffness
Lexaria’s antihypertensive drug development program comes at a time when researchers are documenting poor control of hypertension among both men and women, partly due to suboptimal adherence to existing antihypertension medication
Reasons advanced for the suboptimal adherence include lack of awareness or treatment, increased number of prescribed medications, and major adverse effects of the prescribed drugs
Lexaria has so far shown that its DehydraTECH-CBD is not only effective but also well tolerated and is planning to undertake registered clinical trials in pursuit of the FDA’s approval of the drug candidate

A recent research article published in the Journal of the American Heart Association (“AHA”) unearths data that suggests poorly controlled hypertension among both men and women (https://cnw.fm/q4IM3), a problem global innovator Lexaria Bioscience (NASDAQ: LEXX) is keen on solving.

The researchers, who sought to describe gender-differential disease patterns and results of more than 20.6 million emergency department encounters in the United States from 2016 to 2018, made several observations. Firstly, most ED cardiovascular (“CVD”) visits in the sample were due to hypertensive…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

Knightscope (NASDAQ: KSCP) Robot Show Takes the Spotlight in Lebanon, Ohio

October 14, 2022 12:38:40

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, most recently hosted its Robot Roadshow at Miami Valley Gaming in Lebanon, Ohio, on Oct. 12, 2022. The Robot Roadshow is an engaging experiential event designed to grab attention, forge direct connections with potential clients, and strike up conversations in a compelling fashion.

The announcement from yesterday reads, “The Robot Roadshow has made 63 landings in 23 states and Washington, D.C., to date. Knightscope’s crime-fighting robots tour the U.S. in a space-age, NASA-like ‘pod’ allowing attendees to experience all the technology that is enabling these Autonomous Security Robots (‘ASRs’) to help make sites safer today from Hawaii to Texas to North Carolina.”

To view a short video of a past event hosted by the Los Angeles Police Department, visit https://ibn.fm/n69H9

To view the full press release, visit https://ibn.fm/qhbpB

About Knightscope

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.Knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) Pipeline Addressing Unmet Patient Needs

October 14, 2022 12:38:13

Lexaria Bioscience Corp. (NASDAQ: LEXX), a biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients, developed the patented DehydraTECH(TM) drug delivery technology. “The company has evidenced, through in-vivo, in-vitro and pre-clinical testing, that DehydraTECH delivers more APIs at a faster rate than controls, enabling more effective drug absorption. The testing has so far involved APIs such as cannabidiol (‘CBD’), PDE5 inhibitors, antiviral drugs, and nicotine, each at different stages of product development. This DehydraTECH pipeline, Lexaria says, is addressing severe unmet patient needs. Its DehydraTECH-CBD compound, for example, specifically targets the hypertension space,” reads a recent article. “In the U.S., about 47% of adults, or 116 million people, have hypertension, with only about 24% having the condition under control, while globally, hypertension affects more than 1 billion people, or about 30% of the adult population… Heightened blood pressure has several consequences, including the fact that it makes arteries less elastic, effectively damaging them. This damage, in turn, decreases the blood flow and oxygen to the heart, leading to heart disease. The decreased blood flow also increases the risk of stroke. In extreme cases, hypertension causes death.”

To view the full article, visit https://cnw.fm/sc0lX

About Lexaria Bioscience Corp.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Cepton Technologies (NASDAQ: CPTN) Nova Lidar Earns AutoTech Breakthrough Top Honor

October 14, 2022 12:37:40

Cepton Technologies (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, was recognized for its Nova Lidar sensor in the third annual AutoTech Breakthrough Awards program. A miniature, near-range lidar sensor designed to enhance vehicle safety and enable autonomous driving capabilities, Nova Lidar was named Automotive Sensor Hardware Solution of the year by AutoTech Breakthrough. The leading market intelligence organization annually recognizes top companies, technologies and products throughout the global automotive and transportation technology markets. Other companies that were awarded top awards for their advancements in automotive and transportation technologies included BMW, Toyota and Lyft. Nova Lidar can make driving safer by minimizing perception blind spots in the immediate surroundings of a vehicle; the technology can be seamlessly embedded in places that can be difficult to access, such as the side mirror, tailgate, front grille, rear bumper and headlamp in order to provide accurate detection of smaller targets, such as children, on-road objects and curbs. “We are thrilled to be singled out by AutoTech Breakthrough for this amazing recognition,” said Cepton Technologies vice president of product Brunno Moretti in the press release. “At Cepton, we believe safe autonomy should be accessible to everyone. Nova was designed to enable substantial advancements in the automotive industry and increase vehicle safety across different levels of autonomy. Powered by Cepton’s patented lidar technologies, Nova possesses the versatility needed for scalable deployment in various applications, from ADAS to autonomous driving, from trucking to mobile robotics. We are confident that Nova will fundamentally change the game for near-range sensing in autonomous mobility.”

To view the full press release, visit https://ibn.fm/H3JRS

About Cepton Technologies Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors business. Cepton is also engaged with all other top-10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to automotive customers in the metro Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information about the company, visit www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

CNS Pharmaceuticals (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements

October 14, 2022 12:37:15

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently released its financial results for the second quarter of the fiscal year ended June 30, 2022. “CNS kicked off Q3 2022 with approximately $9 million in cash, and working capital of approximately $10.3 million, which, it is confident, will fund its operations into the 2023 calendar year. Currently, the company is exploring the full potential of its lead product candidate, Berubicin. Results from clinical studies over the last six months have proven fruitful, even as the company continues to work toward approval by the U.S. Food and Drug Administration (‘FDA’),” a recent article reads. “Within the past six months alone, we have executed on a number of clinical and operational advancements, including expanding our global presence with clinical approvals in Spain, France and Switzerland to drive patient enrollment forward, as well as expanding eligibility for patients to participate in our potentially pivotal study of Berubicin for the treatment of Glioblastoma Multiforme (‘GBM’) with our recently amended protocol,” John Climaco, CNSP’s CEO, is quoted as saying.

To view the full article, visit https://ibn.fm/P0Keo

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) Marks Milestone Toward Unique EV Experience

October 14, 2022 12:36:13

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, recently announced a partnership with Watergen Inc., an Israel-based company building technology and equipment that create drinking water from the air, to develop and equip Mullen’s portfolio of EVs with technology that will produce fresh drinking water for in-vehicle consumer and commercial application. “Watergen’s technology of ‘air to clean drinking water’ for vehicles can generate a fresh supply of hot and drinking water for vehicle occupants. This technology is envisioned for Mullen’s fleet of EV cargo vans and can be utilized in both commercial and recreational vehicle settings. The air-to-water systems will provide up to five liters of drinking water daily, directly from the air, while the vehicle is moving and can be used as a freshwater source for the vehicle occupants,” a recent article reads. “The cooperation with Mullen takes us another step towards a cleaner environment and a unique and uncompromising vehicle experience. We are working and will continue to work for a clean future – not just for us but for every person in this world,” Watergen Vice President of Mobility Steve Elbaz is quoted as saying.

To view the full article, visit https://ibn.fm/II11g

About Mullen Automotive Inc.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Knightscope (NASDAQ: KSCP) Signs Acquisition Deal; CEO Featured in Leadership Interview

October 13, 2022

October 13, 2022 12:03:35

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots, announced that it has entered a definitive agreement for the acquisition of CASE Emergency Systems. The transaction is expected to close later this month. According to the announcement, Knightscope is making the strategic move to boost revenues and expand its ability to make a positive impact on the safety of communities nationwide. A leader in blue-light emergency phones and an innovator in next-generation wireless emergency communications technology, CASE gives Knightscope a strategic entry into a nationwide market. Last year, CASE reported profitable revenue of more than $5.4 million. The planned acquisition also gives Knightscope a significant increase in physical presence with more than 7,000 devices currently deployed across the United States, as well as nine production and logistics facilities spread throughout California, Texas and New York and team members located in four states.

In addition, CEO William Santana Li was featured in a recent episode of the Championship Leadership podcast series, which is designed to support anyone committed to becoming leaders in their businesses, families and communities. During the interview, Li joined host Nate Bailey in discussing his journey to founding Knightscope and the company’s mission to make the United States safer. Li talked about the company’s game-changing autonomous security robots and the key role they play in addressing the $2 trillion annual negative economic impact that crime has in the country.

To listen to the full interview, visit https://ibn.fm/k12KZ

To view the full press releases, visit https://ibn.fm/OVrsg and https://ibn.fm/RKmp8

About Knightscope Inc.

NOTE TO INVESTORS: The latest news and updates relating to Knight are available in the company’s newsroom at https://ibn.fm/Knight

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Golden Matrix (NASDAQ: GMGI) Posting Increasing Revenues Quarter after Quarter

October 13, 2022

October 13, 2022 12:03:15

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, currently supports over 645 operators and 6.8 million players in its B2B business and over 229,000 players in its RKings B2C segment. “GMGI’s next generation GM-Ag System – the industry standard – provides access to 10,000+ games while simplifying payment options via seamless integrations with third-party platforms and digital wallets,” a recent article reads. And as the iGaming market continues its rapid pace, Golden Matrix continues to ride the rising wave of industry growth with non-stop consecutive profitable quarters and record-breaking quarterly revenues. “Our ability to generate increasing revenues with quarter after quarter of profitability attests to the strengths of our B2B and B2C platforms. Because of the highly competitive nature of our industry, we are continually upgrading our systems and gaming content offerings to support the needs of our millions of participants,” GMGI CEO Anthony Brian Goodman is quoted as saying.

To view the full article, visit https://ibn.fm/I0Q7H

About Golden Matrix Group Inc.

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

HeartBeam (NASDAQ: BEAT) to Participate at Upcoming LD Micro Main Event Conference

October 13, 2022

October 13, 2022 12:02:50

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, is slated to present at this month’s LD Micro Main Event XV Conference. Scheduled for Oct. 25–27, 2022, the three-day event will be held in Los Angeles. HeartBeam CEO and founder Branislav Vajdic, PhD, will present live during the conference. His presentation will begin at 7:30 p.m. ET on Oct. 25 and can be viewed in person or online. A replay of the presentation will also be available following the event on the HeartBeam investor relations website. Vajdic will also be available for one-on-one meetings with event attendees.

To view the full presentation, visit https://ibn.fm/NQiTf

To view the full press release, visit https://ibn.fm/rdaqR

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Aditxt (NASDAQ: ADTX) Announces Publication of Innovative Mathematical Model

October 12, 2022

October 12, 2022 14:24:21

Aditxt (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced publication of a mathematical model for predicting the durability and rate of decay of neutralizing antibodies to SARS-CoV-2 in a peer-reviewed research paper in the Journal of Theoretical Biology. The publication, titled “A mathematical model of the within-host kinetics of SARS-CoV-2 neutralizing antibodies following COVID-19 vaccination,” describes a model developed with Dr. Lisette de Pillis, a professor of life sciences and mathematics at Harvey Mudd College. NAb inhibit viral binding to the human cell receptor thereby reducing ability to infect the cell. The researchers state that evaluating NAb levels and their durability over time is important in understanding unique immune responses and the likelihood of an individual having protective immunity against infection. The AditxtScore(TM) model utilizes a novel flow-cytometry-based immune monitoring tool to determine levels of NAb following immunization.

To view the full press release, visit https://ibn.fm/i3lQl

About Aditxt Inc.

Aditxt is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Flora Growth (NASDAQ: FLGC) Partnering to Increase Penetration of Colombian Cannabis

October 12, 2022

October 12, 2022 14:24:01

Flora Growth Corp. (NASDAQ: FLGC), a global cannabis brand builder, is increasing the strengths of its supply chain, centered in its 100-hectare (about 247-acre) cultivation facility located in the heart of Colombia’s green climate, by finalizing a three-year distribution agreement with the Misak indigenous tribe’s pharmaceutical arm. “Pharma Indigena Misak Manasr Sas, referred to simply as Manasr, is the tribe’s pharmaceutical enterprise, which in 2020 became the first native community business to receive a license from the national Ministry of Justice for producing legal cannabis for medicinal and scientific use… Flora Growth will assist the tribe with regulatory advice, as well as technical and business support and market promotion for Flora Growth-branded products, particularly as the tribe enters the international supply chain,” a recent article reads. “Through this partnership, we will collaborate with the tribe on the processing and distribution of their Colombian-grown cannabis while offering Manasr a powerful platform for product distribution. In return, Flora will be able to leverage the tribe’s unique regulatory positioning to expedite exports and increase global market penetration of Colombian cannabis goods,” Flora Growth CEO and Chairman Luis Merchan is quoted as saying.

To view the full article, visit https://cnw.fm/PgLWm

About Flora Growth Corp.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria’s (NASDAQ: LEXX) DehydraTECH(TM) Offering Solutions to Hypertension Problem

October 11, 2022

October 11, 2022 13:45:13

Hypertension affects nearly half of all adults in the United States – 47% or 116 million people, some of which are medication-resistant
A recent study from the University of Toledo College of Medicine and Life Sciences concluded gut bacteria might be the cause of medication-resistant hypertension – as demonstrated in rats used to conduct the study
Lexaria’s patented DehydraTECH(TM) technology offers a viable solution for hypertension drug administration and has been received favorably by the FDA during a pre-Investigational New Drug meeting

Hypertension, or high blood pressure, remains one of the world’s most deadly health problems, considered a silent killer because it presents with no symptoms. Nearly half of the adult population in the United States (47% or 116 million) have been diagnosed with hypertension, as defined by having systolic blood pressure greater than 130 mmHg or diastolic blood pressure greater than 80 mmHg or taking medication for the condition (https://cnw.fm/JjXeS). Within this category of adults, some fall into a medication-resistant form of hypertension.

A new study by The University of Toledo College of Medicine and Life Sciences has shown that gut bacteria may be a culprit for medication-resistant hypertension, solving an elusive mystery that has plagued many Americans and their physicians. The study, conducted using lab rats, concluded that…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

Cybin (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Note Mental Health Day

October 11, 2022

October 11, 2022 13:44:38

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), joined partner The Chopra Foundation in recognizing World Mental Health Day, which was Monday, Oct. 11, 2022. The two organizations are working together to research the potential of psychedelic-based therapies for the treatment of mental health and to provide education about the use of psychedelics. Founded by Dr. Deepak Chopra, The Chopra Foundation is a not-for-profit organization dedicated to improving health and well-being. World Mental Health Day was designed to create an opportunity for those with mental health issues, along with advocates, governments, employers, employees and other stakeholders, to recognize progress and identify ways that mental health and well-being can become a global priority. “World Mental Health Day sends a reminder that our mental health is just as important as our physical health,” said Cybin CEO Doug Drysdale in the press release. “At Cybin, mental health and well-being is at the center of everything that we do. It’s this value that drives us to invest our energy and resources to discover new and innovative treatment options for mental health conditions. The commitment from organizations like The Chopra Foundation plays a critical role in this goal, and we are proud to partner with the Foundation to continue to educate and support what is possible for the treatment of mental health from psychedelics.”

To view the full press release, visit https://ibn.fm/7Taao

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

HeartBeam (NASDAQ: BEAT) Appoints Seasoned Veteran as New Chief Medical Officer

October 11, 2022

October 11, 2022 13:44:00

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has named a new chief medical officer. Renowned Stanford cardiologist Peter J. Fitzgerald, MD, PhD, will be joining the HeartBeam executive team and will support the planned advancement of the company’s product pipeline. Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School, Fitzgerald is an interventional cardiologist and has led or participated in more than 175 clinical trials and has published some 650 manuscripts/chapters. He has lectured worldwide and has been principle and founder of 24 medical device companies, leading 18 of them to medium/large-cap life science companies. “We are thrilled to have Dr. Fitzgerald, one of the world’s preeminent opinion leaders in cardiology and digital health, join the HeartBeam leadership team and play a major role in defining best paths to adoption, clinical strategies and partnerships to advance our products in the market,” said HeartBeam CEO and founder Branislav Vajdic, PhD, in the press release. “In addition to his cardiovascular clinical and research expertise, Dr. Fitzgerald has a rich history of developing successful collaborations with partners in the industry and has developed deep connections across the investment and medical communities.”

To view the full press release, visit https://ibn.fm/OFshP

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Golden Matrix Group (NASDAQ: GMGI) Rolling out Expansion Strategy

October 10, 2022 11:16:30

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, owns an extensive portfolio of proprietary technology that has made it a leader in B2B solutions. This is evidenced by the company’s record-breaking revenues and non-stop profitable quarters. “Backed by its stellar financial track record, GMGI is moving into the B2C social gaming sector. The company recently purchased an 80% stake in U.K.-based RKingsCompetitions Ltd. in December 2021, with the rights to acquire the remaining 20%. RKings is a prize competition business based in Ireland and the United Kingdom that offers paid and free entrance routes for customers to win a range of consumer products from automobiles to luxury vacations,” a recent article reads. “GMGI’s permit application for Mexico was recently approved, and others are expected to follow as the company continues to roll out its expansion strategy. ‘This is a logical move for the company, as it opens up compelling opportunities in the Latin America (‘LATAM’) B2C market; and it begins the expansion of the RKings tournament platform to our first region outside of the U.K. and Ireland,’ said GMGI CEO Brian Goodman.”

To view the full article, visit https://ibn.fm/xqj5c

About Golden Matrix Group Inc.

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Rosy Outlook for Global Cannabis Market Boosts Hopes for Flora Growth (NASDAQ: FLGC)

October 10, 2022 11:15:51

Cannabis grower and product maker Flora Growth is developing its own approach to riding troubling economic forces, boasting a 604 percent YOY increase in the H1 reporting period this year
Market analysts predict the global cannabis market’s value will rise during the next five years at a CAGR of 24.3 percent to arrive at annual valuation of $82.3 billion
Flora Growth is levying the potential of recent cooperative agreements to increase the reach of its product distribution pipeline, including new exports to Switzerland, the Czech Republic and the United States
Europe is predicted to be the fastest-growing region for cannabis sales during the next few years as a result of Europeans’ recognition of cannabis’ medical benefits and the ongoing advance of legalization

Cannabis cultivator, brand manufacturer and global distributor Flora Growth (NASDAQ: FLGC) is offering a bit of pain relief to economies battered by recent uncertainty over a costly worldwide pandemic, a war in Europe’s breadbasket and the retail supply chain disruptions that have resulted from them.

The Canadian company with a productive base of operations in Colombia’s fertile greenbelt is licensed to cultivate cannabis on a 100-hectare (about 247-acre) farming facility and then deliver its product to its GMP-certified processing facility in the nation’s capital, where beauty, phytotherapeutic and…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) CEO to Participate in Breakthrough for Brain Tumors 5K

October 10, 2022 11:15:20

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its Chief Executive Officer John Climaco will participate in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run. The event is taking place on Saturday, Nov. 5, 2022, in Los Angeles, California. “The unmet need in brain tumor treatment is immense and knows no geographic borders. As CEO of CNS, I have come to know many brain tumor patients personally and the optimism and strength with which they have all faced this terrible diagnosis is a continuing source of inspiration to me. Supporting these patients, their journey and the challenges they currently endure is not just a priority for us, it is why we do what we do,” Climaco said. “Across the globe there is an urgent need for safe and effective GBM treatment options, and I am proud to participate in the BT5K to support the mission of the ABTA, to help bring hope to patients and families and to raise much needed funds for research.”

To view the full press release, visit https://ibn.fm/e1CPq

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cerberus Sentinel (NASDAQ: CISO) Empowering Organizations to Securely Grow, Innovate

October 10, 2022 11:14:15

Cerberus Sentinel (NASDAQ: CISO), an industry leader in managed cybersecurity and compliance services, was recently named in the top 10 cybersecurity startups and companies by TechRound, the voice of U.K. startups and the U.K.’s fastest-growing platform for startups. According to a recent article that contains excerpts from the TechRound writeup, Cerberus Sentinel is a “nationwide provider of cybersecurity consulting and managed services” specializing in “building a security-centric culture for their clients using an education-based approach. To support the ever-expanding list of needs from their clients, they focus on acquiring top cybersecurity talent who specialize in key areas that complement the service offered.” The article further reads, “As part of CISO’s mission, the company is committed to demystifying and accelerating its clients’ journeys to cyber resilience, empowering organizations to securely grow, operate and innovate. ‘We believe culture is the foundation of every successful cybersecurity and compliance program,’ the company states. This key differentiator sets Cerberus apart from providers who offer their services traditionally, with each solution providing more than just security or compliance improvements. Cerberus designs their services to go beyond delivery to impact an organization’s culture, and the services all work in tandem to achieve this objective.”

To view the full article, visit https://ibn.fm/sXFK9

About Cerberus Cyber Sentinel Corporation

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Lexaria (NASDAQ: LEXX) Working to Address Declining Antihypertensive Intensification

October 7, 2022 13:07:54

Lexaria is a global innovator in drug delivery platforms developing DehydraTECH-CBD as a potential treatment for hypertension
A 2022 study documented a decline in the percentage of patients receiving appropriate treatment intensification over the last ten years
This decline has been attributed to, among other possible reasons, the side effects of antihypertensive drugs
At the same time, only 24% of adults with hypertension have the condition under control, a statistic attributable to the medications’ troublesome side effects
Lexaria’s investigations of its DehydraTECH-CBD have so far presented favorable safety and tolerability data, meaning its drug candidate could offer reprieve to millions looking for antihypertensive drugs with little or no side effects

A recent study published in the American Heart Association (“AHA”) journal Hypertension concluded that “appropriate treatment intensification for older adults with hypertension in the United States was suboptimal over the past decade” (https://cnw.fm/jlEvr). The study results showed the percentage of patients receiving appropriate treatment intensification – described as the addition of an antihypertensive drug to the patient’s care for high blood pressure – had declined over the ten years across all the three blood pressure targets used.

The study sampled adults aged 60 and older who visited their primary care provider and previously had been diagnosed with hypertension, with the researchers focusing on patients that had undergone…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals’ (NASDAQ: CNSP) Advancement of Berubicin Trial Featured in Syndicated Broadcast

October 7, 2022 13:07:16

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it was featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio release covers CNS Pharmaceuticals’ recent announcement that highlights the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. “Our primary focus continues to be on advancing the clinical development of Berubicin as a potential treatment option for this devastating disease. Over the course of this year, we have worked diligently to expand patient eligibility for our potentially pivotal trial and bolster our international presence now realized with the activation of the first two European clinical trial sites,” John Climaco, CEO of CNS Pharmaceuticals, stated in the news release. “This is a true testament to our team’s commitment to and the execution of this important clinical program.”

To view the full press release, visit https://ibn.fm/SB4gt

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Aditxt’s (NASDAQ: ADTX) AditxtScore(TM) Featured in FedEx Video Presentation

October 7, 2022 13:06:43

Aditxt (NASDAQ: ADTX), a biotech innovation company, has announced that its AditxtScore(TM) is featured by FedEx in a video presentation that showcases the various ways in which both companies are playing critical roles in a challenging environment that includes the nation’s response to COVID-19. In the clip, the Aditxt team provides a virtual tour of its AditxtScore(TM) Center and describes the company’s collaboration with scientists and technicians to process samples from around the country to help physicians and health care professionals identify and understand their patients’ immune status. “Aditxt is a biotech innovation company with a very special mission — understanding our immune status and our immune system by the numbers,” said Amro Albanna, co-founder and CEO of Aditxt. “AditxtScore(TM) is a technology and service platform with a proactive approach, meaning the ongoing monitoring of immune status, so we can be better prepared for dealing with such threats as COVID-19. Having a company like FedEx, with their logistical capabilities, is key to scaling AditxtScore(TM).”

To view the full press release, visit https://ibn.fm/Pgi5R

About Aditxt Inc.

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Atlis Motor Vehicles (NASDAQ: AMV) Commences Trading on Nasdaq

October 7, 2022 13:06:18

Atlis Motor Vehicles (NASDAQ: AMV) is a vertically integrated work-focused EV technology ecosystem and battery company developing an electric work truck and the batteries to power it. The company recently announced its commencement of trading on the Nasdaq exchange under the symbol AMV. According to the update, Atlis is among the few companies that has executed its initial public listing through a Reg A financing after raising more than $35M through Reg A and Reg CF crowdfunding offerings. “We are incredibly gratified to have reached this milestone in partnership with our pre-public investors, many of whom have been invested in the company since its inception,” said Atlis CEO Mark Hanchett. “We now enter this exciting next phase of development for Atlis, in which we have achieved the milestone of becoming a publicly listed company, and now look forward to executing on an ambitious business plan to achieve revenue and profitability in an exciting and emerging market with significant opportunities to differentiate ourselves and tremendous potential to create, maintain and increase shareholder value.”

To view the full press release, visit https://ibn.fm/MwU0m

About Atlis Motor Vehicles Inc.

Atlis is a mobility technology company developing products that will power work. The Atlis innovators are building an electric vehicle technology platform for heavy and light duty work trucks used in the agriculture, service, utility, and construction industries. To meet the towing and payload capabilities of legacy diesel-powered vehicles, Atlis is developing proprietary battery technology and a modular system architecture capable of scaling to meet the specific needs of the all-electric vehicle. For more information, visit www.AtlisMotorVehicles.com.

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Cybin (NYSE American: CYBN) (NEO: CYBN) ‘Focused on Adding Targeted IP’

October 6, 2022

October 6, 2022 12:39:33

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today provided an update on its intellectual property (“IP”) progress in support of its research and development strategy. According to the update, Cybin continues to prioritize the development of in-house IP and licensing opportunities that support its active development programs and future novel drug candidates. The company has more than 20 active patent filings — 14 of which were filed this year alone — across six patent families. Additionally, Cybin has entered into multiple licensing agreements that provide additional access to IP from over 15 more patents or patent applications. Collectively, through a combination of internal filings and licensing arrangements, the company has access to more than 35 patents and applications. “Securing and maintaining a robust IP portfolio is an important component of our approach to successful drug development,” said Cybin Chief Executive Officer Doug Drysdale. “We are focused on adding targeted IP that we believe complements our research and development strategy, supports our position as an innovator in the psychedelic therapeutics space, and will continue to build shareholder value.”

To view the full press release, visit https://ibn.fm/8srNq

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Expands Platform to Add 24/7 Heart Monitoring Capability

October 6, 2022

October 6, 2022 12:39:04

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, today announced the expansion of its product portfolio pipeline to serve the growing cardiac device wearable technology market by bringing clinically relevant diagnostic information to patients and clinicians. According to the update, the product pipeline advancement allows for the addition of arrhythmia detection capabilities to address the multibillion global market for atrial fibrillation and other arrhythmia monitoring. “Adding smartwatch connectivity to our platform is a significant development as it extends our portfolio by enabling 24/7 heart monitoring capability,” said Branislav Vajdic, PhD, HeartBeam founder and CEO. “Coupled with our breakthrough AIMIGo solution, we believe the overall HeartBeam system will bring a new and much higher level of diagnostic capability to cardiac patients. We continue to make steady progress in realizing our vision of bringing comprehensive cardiac care to patients anytime, anywhere.”

To view the full press release, visit https://ibn.fm/wPqrl

About HeartBeam Inc.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Silo Pharma (NASDAQ: SILO) to Participate at Dawson James Small Cap Conference

October 6, 2022

October 6, 2022 12:38:27

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is scheduled to participate in the 7th annual Dawson James Small Cap Growth Conference. Silo Pharma CEO Eric Weisblum will present at the event, which is scheduled for Oct. 12, 2022, in Jupiter, Florida. Weisblum’s presentation will include an overview of Silo Pharma’s acquisition and development of intellectual property and technology rights from leading universities and researchers, including the use of the psychedelic drugs. The presentation will also feature a summary of Silo’s the diversified pipeline, which is focused on underserved rare disease, neurological and mental health indications. Silo’s current therapeutics under development show potential for treatment of Alzheimer’s disease, multiple sclerosis, rheumatoid arthritis, stress-induced psychiatric disorders and fibromyalgia. Weisblum will also be available to meet one-on-one with conference attendees.

To view the presentation, visit https://ibn.fm/ZEh9Z

To view the full press release, visit https://ibn.fm/axQz5

About Silo Pharma Inc.

Silo Pharma is a developmental-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research indications such as PTSD, Parkinson’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which the company believes will be transformative to the well-being of patients and the health-care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Nemaura (NASDAQ: NMRD) to Participate at MicroCap Rodeo Windy City Roundup

October 5, 2022

October 5, 2022 11:46:51

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing a daily disposable, wearable glucose sensor and supporting personalized lifestyle coaching programs, will be participating in the MicroCap Rodeo Windy City Roundup 2022 Conference held in Chicago. Slated for Oct. 12–13, 2022, the two-day event will include a presentation by Nemaura Medical CEO Dr. Faz Chowdhury. Chowdhury’s presentation will feature an overview of the company. Chowdhury will be presenting at 1 p.m. CT on Oct. 12; he will also be available throughout the event to meet one-on-one with interested parties.

To view the full presentation, visit https://ibn.fm/gUPaA

To view the full press release, visit https://ibn.fm/8cZwa

About Nemaura Medical Inc.

Nemaura Medical is a medical technology company developing and commercializing noninvasive wearable diagnostic devices. The company is currently commercializing sugarBEAT(R)and proBEAT(TM). sugarBEAT, a CE mark-approved class IIb medical device, is a noninvasive and flexible continuous glucose monitor (“CGM”) that provides actionable insights derived from real-time glucose measurements and daily glucose trend data, which may help people with diabetes and prediabetes to better manage, reverse and prevent the onset of diabetes. Nemaura has submitted a premarket approval application (“PMA”) for sugarBEAT to the U.S. Food and Drug Administration (“FDA”). proBEAT combines noninvasive glucose data processed using artificial intelligence (“AI”) and a digital healthcare subscription service and has been launched in the United States as a general wellness product as part of NMRD’s BEAT diabetes program, which is currently undergoing pilot studies. Additionally, Nemaura has launched a beta trial of Miboko, a metabolic health and well-being program using a noninvasive glucose sensor along with an AI mobile application that helps a user understand how certain foods and lifestyle habits can impact one’s overall metabolic health and well-being. Nemaura believes that up to one-half of the population could benefit from a sensor and program that monitors metabolic health and well-being. Nemaura sits at the intersection of the global type 2 diabetes market, which is expected to reach nearly $59 billion by 2025, the $50-plus billion prediabetic market and the wearable health-tech sector for weight loss and wellness applications, which is estimated to reach $60 billion by 2023. For more information about the company, visit www.NemauraMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Knightscope (NASDAQ: KSCP) Robot Show to Take the Spotlight in Chicago

October 5, 2022

October 5, 2022 11:46:05

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced that its Robot Roadshow will land at Mark Goodman & Associates, 400 N Elizabeth in Chicago, Illinois, on Oct. 7, 2022. The Robot Roadshow is an engaging experiential event designed to grab attention, forge direct connections with potential clients, and strike up conversations in a compelling fashion.

The announcement reads, “The Chicago Roadshow landing will be guided by Knightscope experts both virtually and in person. Visitors will be able to interact directly with each of the ASRs and see the Knightscope Security Operations Center (‘KSOC’) user interface in action. Clients, investors and the media are all welcome to attend to learn more about Knightscope.”

There is no charge to participate in, or visit, the Roadshow. However, available slots fill up quickly. Appointments are recommended and can be made by visiting the following link: https://calendly.com/robotroadshow/

To view a short video of a past event hosted by the Los Angeles Police Department, visit https://ibn.fm/n69H9

To view the full press release, visit https://ibn.fm/6IzuY

About Knightscope

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About ESGWireNews

ESGWireNews delivers up-to-date information and actionable intelligence on public companies committed to sustainable corporate practices. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), ESGWireNews provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. Environmental, social and governance (ESG) issues aren’t just buzzwords. The growing threat of climate change has moved large investors, like pension funds and insurance reserves, to action and screen investments based on sustainability and environmental impact. ESG criteria are increasingly guiding the investment choices of large institutional investors, and blue-chip companies have taken notice. ESGWireNews aims to uncover the emerging growth companies following their lead. If you’re interested in aligning your values with your investment portfolio, you’re in the right place.

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

Cepton (NASDAQ: CPTN) Poised as Consensus Points to Lidar as Essential Solution

October 5, 2022

October 5, 2022 11:45:33

Cepton (NASDAQ: CPTN), a developer of lidar-based solutions that help enable Advanced Driver Assistance Systems (“ADAS”), autonomous vehicles (“AVs”), smart cities, connected spaces, and smart industrial applications, is ideally poised as expert opinions concerning AV safety lean in favor of using lidar technologies in addition to HD cameras. “The safety of AVs and ADAS hinges on the ability of vehicle’s systems to sense surrounding objects. Both HD cameras and lidar have their benefits and drawbacks; however, lidar is coming out ahead as the technology advances and costs come down. Industry experts like Volkswagen CEO Herbert Diess confirm the growing consensus that lidar is an essential solution. According to Diess, Level 3 driving automation is safer with lidar because it offers redundant perception to 360-degree camera systems,” a recent article reads. “Cepton is leading the way in scaling up lidar for mass-market deployments. In addition to its significant ADAS lidar series production award with Koito on the General Motors business, Cepton has expanded its lidar use cases across smart infrastructure… Cepton is also engaged with the other top 10 global automotive OEMs with the aim of making lidar a standard safety feature in all vehicles.”

To view the full article, visit https://ibn.fm/mPipH

About Cepton Inc.

Cepton is a Silicon Valley innovator of lidar-based solutions for automotive (“ADAS/AV”), smart cities, smart spaces and smart industrial applications. With its patented lidar technology, Cepton aims to take lidar mainstream and achieve a balanced approach to performance, cost and reliability, while enabling scalable and intelligent 3D perception solutions across industries. Cepton has been awarded a significant ADAS lidar series production award with Koito on the General Motors business. Cepton is also engaged with all other top 10 global OEMs. Founded in 2016 and led by industry veterans with decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high-performance, high-quality lidar solutions. Cepton is headquartered in San Jose, California, and has a center of excellence facility in Troy, Michigan, to provide local support to the OEM and tier 1-studded Detroit area. Cepton also has a presence in Germany, Canada, Japan, India and China to serve a fast-growing global customer base. For more information, visit the company’s website at www.Cepton.com.

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

CNS Pharmaceuticals (NASDAQ: CNSP) Poised to Bring ‘Potentially Impactful’ Therapy to GBM Patients

October 4, 2022 11:48:15

CNS Pharmaceuticals (NASDAQ: CNSP), a preclinical stage biotechnology company specializing in developing novel treatments for brain tumors, has focused on its lead drug candidate, Berubicin, to potentially treat glioblastoma (“GBM”). “CNS has since made significant headway, even receiving FDA Fast Track Designation, which now offers it an accelerated path to approval for Berubicin. ‘With this designation, we now have an accelerated pathway to approval for Berubicin and a clear opportunity to more expediently bring this potentially impactful investigational therapy to individuals battling this challenging disease,’ noted CNS CEO John Climaco. GBM’s median survival from initial diagnosis is less than 15 months, with a 2-year survival rate of 26-44%. Globally, it affects 5 out of 100,000 people, making it the most common and devastating primary malignant brain tumor affecting adults,” a recent article reads. “CNS hopes its research will offer a solution to the millions of people currently dealing with GBM globally. Given how much promise Berubicin has shown, its management is optimistic that with additional studies, it will get to offer a much-needed treatment option for the condition.”

To view the full article, visit https://ibn.fm/CGHvR

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) K5 ASR to Enhance Security at Orange County Convention Center

October 4, 2022 11:47:15

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced a partnership with the award-winning, Orlando, Florida-based Orange County Convention Center (“OCCC” or the “Center”). A leader in creating safe, memorable experiences for visitors from around the world, the OCCC will begin utilizing Knightscope’s K5 Autonomous Security Robot (“ASR”) to enhance security and operational efficiency at the massive facility. According to the announcement, this represents Knightscope’s first-ever convention center contract and marks the company’s entrance into this area of the security market.

“We are thrilled that Knightscope and the OCCC developed this partnership to enhance the safety and security of our campus by adding a K5 autonomous robot to the Security Division,” said Isiah White, OCCC security manager. “This partnership demonstrates the Center’s commitment to public safety and cutting-edge innovation, and we look forward to the future of our security operations.”

To view the full press release, visit https://ibn.fm/iT6Mv

About Knightscope

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About ESGWireNews

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

Silo Pharma (NASDAQ: SILO) Preparing for Ketamine Tech FDA Pre-IND Package

October 4, 2022 11:46:49

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is collaborating with Premier Consulting to prepare a pre-investigational new drug (“IND”) package and meeting request with the United States Food and Drug Administration (FDA) for SPC-26, the company’s novel topical formulation of ketamine for the treatment of fibromyalgia. The company is planning to pursue a 505(b)(2) regulatory pathway for novel topical formulation of ketamine. According to the company, Premier Consulting will assist with the development of SILO’s nonclinical, clinical, clinical pharmacology, and biopharmaceutics strategy and program to be proposed to the FDA. Silo is planning to submit the pre-IND meeting request for collaborative discussions with the FDA in anticipation of the filing a clinical IND package. “We are confident that our highly constructive preclinical work on SP-26 will offer strong support for our pre-IND package as we seek to advance our time-released ketamine delivery system into the clinic,” said Silo Pharma CEO Eric Weisblum in the press release. “We intend to pursue the 505(b)(2) regulatory pathway and have engaged Premier Consulting as a true strategic partner to pave the way for productive discussions and alignment with the FDA.”

To view the full press release, visit https://ibn.fm/RoAOh

About Silo Pharma Inc.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Expands Distribution to Three Industry-Leading Countries

October 4, 2022 11:46:02

Flora just announced the first successful export of Colombian high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD isolate to the United States
Luis Merchan, the company’s CEO, has described this as a “major milestone,” one that further defines the company’s revenue pipeline
He pointed out the increasing demand for Flora’s high-quality, high-margin flower and derivatives from its cultivation operation in Colombia, terming it as a testament to the Flora team’s ability to execute in a very complex global regulatory environment
Flora also earned the Best M&A Deal award at Benzinga’s 2022 Cannabis Capital Conference in Chicago, an award that recognized the company’s strategic M&A objectives, including acquiring products, expertise, expanding distribution, and customers

On September 26, Flora Growth (NASDAQ: FLGC) announced the first successful export of Colombian high-CBD dried cannabis flower to Switzerland and the Czech Republic, as well as CBD, isolate to the United States. Luis Merchan, Chairman and Chief Executive Officer (“CEO”) of the company, described this as a “major milestone,” one that further defines Flora’s revenue pipeline. The company also launched its commercial website, where interested buyers can expedite the processing of orders and learn about the company’s cultivation and growth practices (https://cnw.fm/l07N0).

With the global CBD market having achieved impressive growth thus far and showing even greater potential growth in the coming years, Flora is positioning itself as a key industry player, looking to take…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

Freight Technologies (NASDAQ: FRGT) Positioned for Growth Amid Prevailing Market Trends

October 4, 2022 11:45:17

Freight Technologies (NASDAQ: FRGT), a company that simplifies cross-border shipping and daily carrier operations through its B2B marketplace Fr8App, recently filed a Form F-1 with the Securities and Exchange Commission (“SEC”). “In the recently filed Form F-1, Fr8Tech, a British Virgin Islands-incorporated technology company developing supply chain optimization and automation solutions and providing its Fr8App platform for B2B cross-border shipping, registered more than 19 million ordinary shares for resale by selling shareholders identified in the form… Fr8Tech CEO Javier Selgas commented, ‘We are incredibly proud of our team, and thank them for their work and dedication to deliver our F-1 registration, which positions us to be able to grow as a public company. Delivering our registration statement puts us in a position to continue to work with the capital markets to foster the growth of our company,’” a recent article reads. “The efforts to grow the company are timely considering the prevailing trends in the North American freight transportation market… Fr8Tech, which is snugly positioned to benefit from this growth, expects the market to continue growing at rates at least equal to historical values, according to the recent filing.”

To view the full article, visit https://ibn.fm/sbnBl

About Freight Technologies Inc.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

Business Booming for Golden Matrix (NASDAQ: GMGI) as Online Gambling Continues Growth

October 3, 2022 11:33:36

Data Bridge Market Research forecasts a 13.7% CAGR for the casino online gambling market to reach $144.74 billion in 2028
Golden Matrix Group is demonstrating growth in both its B2B and B2C businesses, as it prepares to enter the Mexican markets
GMGI revenue for the first nine months of fiscal 2022 was $26.46 million, up 237% from a year earlier, while the company notched its 16^th consecutive profitable quarter

For decades, there was little substantial innovation in the gambling industry and then along came the miracle of the internet and changed everything with the emergence on online gaming. Still, most traditional casino operators were slow to embrace the digital opportunity until the COVID-19 pandemic and subsequent lockdowns limited travel and shuttered their doors. That sparked a renaissance and provided a growth opportunity for companies like Golden Matrix Group (NASDAQ: GMGI), a provider of turnkey and white label gaming platforms, Esports technology and gaming content.

Even with casinos opened again, the trend towards digital gaming is accelerating with no indications it will slow. Data Bridge Market Research this month forecast 13.7% compound annual growth for the casino online gambling market to reach $144.74 billion in 2028. Drivers abound, including increasingly…

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems Los Angeles, California www.TinyGems.net 310.299.1717 Office [email protected]

TinyGems is part of the InvestorBrandNetwork

Lexaria Bioscience (NASDAQ: LEXX) Focusing on Mainstream Applications of DehydraTECH(TM)

October 3, 2022 11:32:56

Lexaria is the drug delivery platform innovator behind the disruptive, patented DehydraTECH(TM) technology
DehydraTECH is designed to enhance the performance of fat-soluble active pharmaceutical ingredients (“APIs”), molecules, and drugs by increasing their bioavailability
Through animal and human studies, Lexaria has shown that DehydraTECH increases the bioavailability of antiviral drugs, CBD, oral nicotine and more
The company is focusing on multiple mainstream applications of its technology that rerrcould address serious unmet patient needs
Lexaria is currently keen on developing a potential treatment for hypertension

Last summer, drug delivery platform innovator Lexaria Bioscience (NASDAQ: LEXX) announced a review of its successful 2021 antiviral drug program. The program, which aimed to determine whether the processing of leading antiviral drugs using its patented DehydraTECH could exhibit evidence of superior oral absorption relative to controls; whether DehydraTECH processing of these compounds would preserve the expected viral inhibitory performance; and whether DehydraTECH does not alter or degrade the drug molecules chemically, met all three of these objectives (https://cnw.fm/Nncql).

Lexaria specifically probed the bioavailability of five DehydraTECH-processed antiviral drugs for SARS-CoV-2, HIV/AIDS, and other infectious diseases from three drug classes, evidencing significant gains with up to a three-fold increase in oral drug delivery into the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Receives US Patent for Exclusive ECG Patch Monitor

October 3, 2022 11:32:02

The USPTO issued a patent for BEAT’s 12-lead electrocardiogram (“ECG”) patch monitor for detection of ACS and cardiac arrhythmia
HeartBeam has developed the only 3D-vector ECG platform for heart-attack detection anytime, anywhere
BEAT’s patch technology could have a disruptive effect on the ECG patch market with its ischemia detection capability

News about heart attacks and other life-threatening cardiovascular issues is alarming. Heart disease is the leading cause of death for men, women, and people of most racial and ethnic groups in the United States (https://ibn.fm/FN4BR), and recent reports suggest that COVID-19 may cause heart problems (https://ibn.fm/7QAky) and that the incidence of heart attacks in people under age 40 is increasing (https://ibn.fm/lFzjh). Many companies are working to provide support for this growing problem, including HeartBeam (NASDAQ: BEAT), a cardiac technology company that just received a patent for a proprietary device (https://ibn.fm/RA8EP).

According to a recent announcement from the company, the United States Patent and Trademark Office issued a patent for BEAT’s 12-lead electrocardiogram (“ECG”) patch monitor for detection of acute coronary syndrome (“ACS”) and cardiac arrhythmia. The new patent expands on a previously granted…

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

D-Wave Quantum (NYSE: QBTS) Offers Quantum Solutions to Solve Optimization Challenges

October 3, 2022 11:31:31

40% of large enterprises are already experimenting with quantum computing to solve some of their most complex problems, according to 451 Research
Optimization problems make up a significant portion of the enterprise problem universe, and annealing quantum computers are uniquely effective at solving these types of problems
D-Wave is the only provider building both annealing and gate-model quantum computers that provide opportunities for businesses looking to optimize at scale

The classical computer architecture relies on binary coding, which assigns values of 0 or 1, limiting the decision-making process to a return result of one. The binary space cannot handle large volumes of data with many variables and requires those loading the data to compress, reduce, or limit the data being processed, resulting in lower quality solutions. Businesses representing a variety of industries, like manufacturing, logistics, financial services, and life sciences, rely on optimization to help them tackle common obstacles and problems in the computing world – which binary coding cannot support at scale.

The quantum computing framework is multi-dimensional. Using qubits, quantum computers can represent superposition states between 0 and 1, allowing them to represent an exponentially larger state of space to process and store data. With the limitations of classical computers becoming more…

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About BillionDollarClub

BillionDollarClub (BDC) is the exclusive home of the biggest and brightest companies covered by IBN, a financial news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution to millions of social media followers, and (5) a full array of corporate communications solutions. This is the place you want to be, where every covered company has a market cap in excess of $1 billion. By cutting through the overload of information in today’s market, BDC brings its clients unparalleled visibility, recognition and brand awareness. While IBN’s client list includes companies big and small, BillionDollarClub is the gold standard.

To receive SMS text alerts from BillionDollarClub, text “Billion” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BillionDollarClub.com

Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: http://IBN.fm/Disclaimer

BillionDollarClub (BDC)
Los Angeles, California
www.BillionDollarClub.com
310.299.1717 Office
[email protected]

BillionDollarClub is part of the InvestorBrandNetwork.

Knightscope (NASDAQ: KSCP) Robot Show to Take the Spotlight in Illinois

September 30, 2022

September 30, 2022 11:14:51

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced that its Robot Roadshow will land in the suburbs of Chicago at Huntley Village Green, in Huntley, Illinois, on Oct. 3, 2022. The Robot Roadshow is an engaging experiential event designed to grab attention, forge direct connections with potential clients, and strike up conversations in a compelling fashion.

The announcement reads, “The Huntley Roadshow landing will be guided by Knightscope experts both virtually and in person. Visitors will be able to interact directly with each of the ASRs and see the Knightscope Security Operations Center (‘KSOC’) user interface in action. Clients, investors and the media are all welcome to attend to learn more about Knightscope.”

To view a short video of a past event hosted by the Los Angeles Police Department, visit https://ibn.fm/n69H9

To view the full press release, visit https://ibn.fm/8JB1o

About Knightscope

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About ESGWireNews

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

Silo Pharma (NASDAQ: SILO) Secures $5.75M in Underwritten Public Offering

September 30, 2022

September 30, 2022 11:14:20

Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters’ over-allotment option to purchase 150,000 additional shares of common stock, each at a public offering price of $5.00. Silo Pharma’s common stock began trading on the Nasdaq Capital Market on Sept. 27, 2022, under the symbol SILO. The company secured $5,750,000 million in gross proceeds from the offering, before deducting underwriting discounts and commissions and other expenses. Silo Pharma intends to use the net proceeds for product development, marketing, working capital and general corporate purposes. In addition, a portion of the proceeds may be used for acquisitions of complementary businesses, technologies or other assets. Laidlaw & Company (U.K.) Ltd. acted as sole book-running manager for the offering.

To view the full press release, visit https://ibn.fm/K4pyF

About Silo Pharma Inc.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Announces Participation in Two Investor Events

September 30, 2022

September 30, 2022 11:13:54

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, will be attending and presenting at two upcoming investor conference: the Dawson James Small Cap Growth Conference and The ThinkEquity Conference. Slated for Oct. 12, 2022, the Dawson James event will be held in Jupiter, Florida. HeartBeam founder and CEO Branislav Vajdic, PhD, will be joined by chief financial officer Rick Brounstein and chief business officer Jon Hunt, PhD, at the conference to deliver the company’s presentation and also meet one-on-one with meeting attendees. The presentation is scheduled for 10 a.m. ET; it can be viewed live or replayed after the event on the HeartBeam investor relations website. Vajdic, Brounstein and Hunt will also participate in the ThinkEquity event, which will be held in New York City on Oct. 26, 2022. The company managers will deliver a presentation at 4:30 p.m. ET and will also be available to meet one-on-one with those in attendance. The ThinkEquity presentation can also be viewed live.

To view the presentations, visit https://ibn.fm/4VCV0 and https://ibn.fm/Hgwcq

To view the full press release, visit https://ibn.fm/gEOAn

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart-attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Golden Matrix Group (NASDAQ: GMGI) Rides iGaming Wave with Record Revenues

September 29, 2022 13:00:37

iGaming market expected to double from $173 billion to over $340 billion by 2027
GMGI recently posted record-breaking Q3 revenue results, 16 non-stop profitable quarters
GMGI’s industry-standard GM-Ag System provides access to 10,000+ games, simplifies payment options, leverages data analytics to provide total 360-degree performance visibility

The iGaming market continues its rapid pace of growth with expectations it will double from $173 billion to over $340 billion by 2027 (https://ibn.fm/8JO3m). Golden Matrix Group (NASDAQ: GMGI), a developer and licensor of online gaming platforms and systems, continues to ride the rising wave of industry growth with non-stop consecutive profitable quarters and record-breaking quarterly revenues (https://ibn.fm/AATls).

“Our ability to generate increasing revenues with quarter-after-quarter of profitability attests to the strengths of our B2B and B2C platforms,” said GMGI CEO Anthony Brian Goodman. “Because of the highly competitive nature of our industry, we are continually upgrading our systems and…

NOTE TO INVESTORS: The latest news and updates relating to GMGI are available in the company’s newsroom at https://ibn.fm/GMGI

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems Los Angeles, California www.TinyGems.net 310.299.1717 Office [email protected]

TinyGems is part of the InvestorBrandNetwork

Lexaria Bioscience (NASDAQ: LEXX) Addressing Hypertensive Patients with DehydraTECH-CBD

September 29, 2022 13:00:02

Lexaria is a global innovator in drug delivery platforms whose lead technology is DehydraTECH(TM)
Studies have shown that DehydraTECH increases the intestinal bioabsorption of bioactive compounds by as much as 27 times, hence resulting in greater bioavailability; pre-clinical and human studies have demonstrated that DehydraTECH-CBD enables absorption increases of between 100% and 500% The studies have also shown that DehydraTECH-CBD results in a rapid and sustained drop in blood pressure among hypertension patients
Lexaria, which believes there is a significant unmet demand for cost-effective hypertensive treatments with few or no side effects, is working toward commercializing DehydraTECH-CBD to satisfy this demand

Currently, roughly 20% of people diagnosed with hypertension take medication, with the remaining majority noting that the medications’ side effects substantially outweigh the benefits. This has often constrained the fight against hypertension, the most common cardiovascular disease worldwide, which affects more than one billion people and is associated with long-term morbidities such as heart disease, stroke, and even death.

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, believes the hesitance or refusal to take medication presents a significant unmet demand for more tolerable, cost-effective anti-hypertensive treatments and has been working to bring such treatments to the…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

DoubleDown Interactive (NASDAQ: DDI) Announces Donation to American Cancer Society

September 29, 2022 12:59:26

DoubleDown Interactive (NASDAQ: DDI), a leading gaming company that delivers unique player experiences across a variety of genres, will donate $10,000 to the American Cancer Society; the company is making the donation in honor of Breast Cancer Awareness Month, which begins on Oct. 1. Millions of fans around the world play DoubleDown Casino every day, and the company will encourage its players to support the cause by participating in a play-to-enter giveaway called Spin for Cures. Whether they’re playing on their desktop or mobile devices, players will be able to contribute to the cause and learn more about what the American Cancer Society does through the campaign. An official from the American Cancer Society noted that the organization appreciates the support of DoubleDown Interactive and its players, which helps ensure the society can continue to fund cutting-edge breast cancer research and provide critical programs and services to those in need. “Breast Cancer Awareness Month has been an important focus of our charitable outreach efforts for years,” said Doubledown CEO In Keuk Kim in the press release. “This is an issue which resonates with all of us as well as our players, and we are proud to support the American Cancer Society.”

To view the full press release, visit https://ibn.fm/VSkGQ

About DoubleDown Interactive Co. Ltd.

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Aditxt (NASDAQ: ADTX) Regains Compliance with Nasdaq Listing Requirements

September 29, 2022 12:58:56

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced its receipt of confirmation from the Nasdaq Stock Market LLC Hearing Panel that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). In addition, Nasdaq confirmed that Aditxt meets the stockholders’ equity requirement in Listing Rule 5550(b)(1) and all other applicable criteria for continued listing. Amro Albanna, co-founder, chairman and CEO of Aditxt, said that the company’s recent completion of a reverse stock split and closing of a $20 million public offering were key to the company’s successful Nasdaq compliance and continued progress within each of its programs toward commercialization. These programs include AditxtScore(TM), Adimune(TM) and Adivir(TM).

To view the full press release, visit https://ibn.fm/s13Rl

About Aditxt Inc.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) Robot Roadshow Makes Ohio Stop

September 29, 2022 12:58:33

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, is slated for a visit in New Albany, Ohio, on Sept. 29, 2022. The company’s Robot Roadshow is a creative event designed to provide hands-on experiences for those interested in its Autonomous Security Robots (“ASRs”). The unique event is an engaging experiential event for potential clients that grabs attention, forges direct connections and sparks conversations. So far, the roadshow has made 59 stops in 23 states and Washington, DC.

The event features a tour of Knightscope’s crime-fighting robots. The robots travel in a space-age, NASA-like “pod” where participants can experience the technology that enable ASRs to patrol client sites and provide added security and surveillance. In New Albany, Knightscope experts will be available both virtually and in person to guide the experience and assist visitors in direct interaction with the robots. The company invites clients, investors and the media to attend to any roadshow stop; reservations are encouraged, and no fee is required.

To reserve a spot during a roadshow stop, visit https://ibn.fm/Jim0s

To view the full press release, visit https://ibn.fm/C9HzY

About Knightscope Inc.

NOTE TO INVESTORS: The latest news and updates relating to Knight are available in the company’s newsroom at https://ibn.fm/Knight

About ESGWireNews

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

CNS Pharmaceuticals (NASDAQ: CNSP) Activates First European Sites for Clinical Trial

September 29, 2022 12:58:11

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced the activation of its first clinical trial sites in Europe for the ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (“GBM”), one of the most aggressive types of brain cancer. According to the update, the first European clinical trial sites in France and Spain are now open and actively enrolling patients. “Our primary focus continues to be on advancing the clinical development of Berubicin as a potential treatment option for this devastating disease. Over the course of this year, we have worked diligently to expand patient eligibility for our potentially pivotal trial and bolster our international presence now realized with the activation of the first two European clinical trial sites,” said John Climaco, CEO of CNS Pharmaceuticals. “This is a true testament to our team’s commitment to and the execution of this important clinical program. We are grateful for the tremendous support from the clinical staff and remain dedicated to driving patient enrollment as quickly and efficiently as possible. We look forward to continuing to build momentum and bringing Berubicin across the finish line to unlock its greatest potential. As long as the unmet medical need in GBM remains, we will continue our fight in earnest to bring hope to patients and families globally.”

To view the full press release, visit https://ibn.fm/RaJ5q

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The company’s lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Additionally, the company is advancing the development of its WP1244 drug technology portfolio, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers, pancreatic, ovarian, and lymphomas. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) Shares Info about New Sport Crossover

September 29, 2022 12:55:37

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, is providing a first look at its newest upcoming vehicle offering. The company released information about the FIVE RS, an ultrahigh-performance EV sport crossover. According to the announcement, Mullen’s newest EV can go from 0 to 60 mph in 1.9 seconds and comes with all-wheel drive, a two-speed gearbox, 800-volt architecture and 1,000-plus horsepower. Mullen plans to feature the FIVE RS in the second leg of its test-drive tour, beginning in April. Because of the vehicle’s high-powered capabilities, potential buyers won’t be able to test drive the vehicle; however, they will be able to ride in the Mullen FIVE RS with a professional IndyCar race car driver at the wheel.

To view the full article, visit https://ibn.fm/IQE35

About Mullen Automotive Inc.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Cerberus Sentinel (NASDAQ: CISO) Leveraging Integrated Approach to Reduce Noise

September 29, 2022 12:54:47

Cerberus Sentinel (NASDAQ: CISO) is helping organizations create a culture of security, allowing them to quantify, define and capture a return on investment from information technology and cybersecurity spending. “Cerberus Sentinel has established a reputation for its integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. The company is dedicated to pulling disparate technologies, teams and vendors together to help its clients enjoy a simpler and more successful journey to cyber resilience,” reads a recent article. “A firm believer that cybersecurity is a culture rather than a product, Cerberus Sentinel works closely with its clients to integrate compliance and security into an organization-wide culture of cybersecurity. CISO provides a wide range of high-quality offerings, including audit and compliance, security operations center services, security engineering, virtual chief information security officer services, incident response, certified forensics, technical assessments, and cybersecurity training. In contrast to the majority of cybersecurity firms that specialize in a specific technology or service, Cerberus Sentinel seeks to differentiate itself by remaining technology agnostic, focusing on accumulating highly sought-after subject matter experts.”

To view the full article, visit https://ibn.fm/Rf0ua

About Cerberus Cyber Sentinel Corporation

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

D-Wave Quantum (NYSE: QBTS) Providing Quantum Applications for Life Sciences Industry

September 28, 2022 11:47:37

Quantum computing provides companies with promising new technologies that have the potential to streamline the drug development and patient trial processes, potentially finding greater efficiencies than classical computing systems
D-Wave has demonstrated that annealing quantum computers could play a transformational role in the life sciences industry, as illustrated by the company’s work with Menten AI and its achievements in protein design

The life sciences industry is centered around researching, developing, and manufacturing products to improve the lives of humans – including drug discovery. Drug discovery is a high-risk, high-reward field that helps to deliver life-changing clinical benefits to millions of patients.

Through quantum computing, pharma and biotech companies may be able to stack the odds in their favor through promising new technologies. D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems and software, focused on delivering customer value via…

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About BillionDollarClub

To receive SMS text alerts from BillionDollarClub, text “Billion” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.BillionDollarClub.com

Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: http://IBN.fm/Disclaimer

BillionDollarClub (BDC)
Los Angeles, California
www.BillionDollarClub.com
310.299.1717 Office
[email protected]

BillionDollarClub is part of the InvestorBrandNetwork.

Freight Technologies’ (NASDAQ: FRGT) CFO and President Present at H.C. Wainwright Conference

September 28, 2022 11:47:00

Fr8Tech’s August 15, 2022, corporate update formed the backbone for its presentation at the H.C. Wainwright 24th Annual Global Investment Conference held from September 12-14, 2022
The company was represented by Paul Freudenthaler and Mike Flinker, who also talked about the company’s role in revolutionizing cross-border shipping, and the role of AI and machine learning in solving current logistical problems in the industry within the NAFTA region
Fr8Tech remains committed to exploring new ways to create more value for its clients and streamline the region’s cross-border shipping process, and leveraging technology
Javier Selgas, the company’s CEO, maintains that Fr8Tech anticipates steady long-term growth, especially as the market conditions improve and fuel prices stabilize

Since its founding in 2015, Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”) has been known for developing advanced technological solutions, including AI and machine learning, to optimize and automate the supply chain process, offering a platform for cross-border shipping in the NAFTA region for business-to-business (“B2B”) clients. Beginning in 2019, it refocused its B2B offerings away from freight forwarders and towards business clients directly, without an intermediary and supported by the Company’s staff.

On August 15, 2022, Freight Technologies provided its latest corporate update. Of note was the filing of a Form F-1 with the United States Securities and Exchange Commission (“SEC”) in a move which Javier Selgas, the company’s Chief Executive Officer (“CEO”), sees positioning Fr8Tech for continued growth as…

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems Los Angeles, California www.TinyGems.net 310.299.1717 Office [email protected]

TinyGems is part of the InvestorBrandNetwork

Silo Pharma (NASDAQ: SILO) Announces Uplisting to Nasdaq, Pricing of $5M Offering

September 28, 2022 11:46:12

Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price to the public of $5.00 per share. Silo Pharma expects $5,000,000 in gross proceeds from the offering and intends to use the net proceeds for product development, marketing, working capital and general corporate purposes. In addition, a portion of the proceeds may also be used for acquisitions of complementary businesses, technologies or other assets. As a result of the offering, the company’s common stock commenced listing on the Nasdaq Capital Market on Sept. 27, 2022, trading under the ticker symbol SILO. The offering is expected to close on or about Sept. 29, 2022, subject to customary conditions. The company has also granted a 45-day option to the underwriter to purchase up to an additional 150,000 shares of common stock at the public offering price, less the underwriting discount, to cover over-allotments, if any. Laidlaw & Company (U.K.) Ltd. is acting as sole book-running manager for the offering.

To view the full press release, visit https://ibn.fm/Jm1A0

About Silo Pharma Inc.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cybin (NEO: CYBN) (NYSE American: CYBN) to Obtain Catalog of Psychedelic-Based Compounds

September 28, 2022 11:45:41

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its wholly owned subsidiary, Cybin IRL Limited, have signed a deal with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules. The agreement for the license will provide access to large catalog of compounds that are complementary to Cybin’s preclinical assets and that strengthen the company’s drug-discovery and development platform to build future potential novel drug candidates. The agreement also supports Cybin’s broad intellectual property portfolio of innovative psychedelic-based molecules. According to the announcement, Cybin has paid Mindset a $500,000 one-time license fee; the agreement also outlines additional payments based on the successful completion of certain future milestones. “This exclusive license bolsters the breadth of Cybin’s IP holdings while adding a significant number of compounds to our growing library of psychedelic derivative drug development candidates,” said Cybin CEO Doug Drysdale in the press release. “In addition to the value created from progressing our clinical-stage programs for CYB003 and CYB004, our discovery and development engine will continue to be an asset for the company as we leverage strategic M&A opportunities, including this one, to strengthen our competitive advantage and support our goal of developing new and innovative psychedelic treatments for mental health conditions and other areas of high unmet need. We are pleased to work with Mindset who, like Cybin, has a deep-rooted understanding of psychedelic science.”

To view the full press release, visit https://ibn.fm/8qBVW

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.PsychedelicNewsWire.com

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Aditxt (NASDAQ: ADTX) Issues Update Following Reverse Split, Closing of $20M Offering

September 28, 2022 11:44:52

Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. The company today provided shareholders with a corporate update following the completion of a reverse stock split and closing of a previously announced $20 million public offering. “Aditxt’s key to success is multifaceted and tied to the success of each of the company’s programs, which currently include AditxtScore(TM), Adimune(TM) and Adivir(TM). The successful completion of the reverse stock split and the closing of our public offering were critical to continuing the progress within each of these programs toward commercialization, and as we work toward regaining compliance with Nasdaq’s continued listing requirements,” said Amro Albanna, co-founder, chairman and CEO of Aditxt. “We are extremely encouraged by the support and adoption our technologies are receiving in various health care sectors as we track toward key inflection points in 2023.”

To view the full press release, visit https://ibn.fm/1tIMY

About Aditxt Inc.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Knightscope (NASDAQ: KSCP) to Take Spotlight with Robot Show in Indianapolis

September 28, 2022 11:44:16

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced that its Robot Roadshow will land at 714 N Senate Avenue in Indianapolis, Indiana, on Sept. 27, 2022. The Robot Roadshow is an engaging experiential event designed to grab attention, forge direct connections with potential clients, and strike up conversations in a compelling fashion.

The announcement reads, “The Robot Roadshow has made 58 landings in 22 states and Washington, D.C., to date. Knightscope’s crime-fighting robots tour the U.S. in a space-age, NASA-like ‘pod’ allowing attendees to experience all the technology that is enabling these Autonomous Security Robots (‘ASRs’) to help make sites safer today from Hawaii to Texas to North Carolina.”

To view a short video of a past event hosted by the Los Angeles Police Department, visit https://ibn.fm/n69H9

To view the full press release, visit https://ibn.fm/ye9Sc

About Knightscope

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About ESGWireNews

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

HeartBeam (NASDAQ: BEAT) Tech Enabling 12-Lead ECG Receives Patent from USPTO

September 28, 2022 11:43:42

HeartBeam (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, has been granted a patent from the United States Patent and Trademark Office (“USPTO”). The patent covers proprietary technology that allows the HeartBeam AIMIGo(TM) credit card-sized device to enable a 12-lead ECG anytime or anywhere. According to the announcement, the innovative tech and AIMIGo device makes it possible for a patient to record signals outside of a medical setting with a diagnostic synthesized 12-lead ECG that is immediately transmitted to a physician for review and diagnosis; the now-patented HeartBeam technology is designed to assist the physician in quickly and accurately identify a heart attack, or myocardial infarction. “This patent provides additional intellectual property protection for our breakthrough AIMIGo technology offering 12-lead ECG capability in the form of a credit card-sized device with the same footprint as the single-lead products currently in the market today,” said HeartBeam CEO and founder Branislav Vajdic, PhD. “Our 12-lead AIMIGo technology, which is part of our granted patent, offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care. This could reduce the critical time to intervention for heart attack patients, saving lives and reducing healthcare costs by ruling out a heart attack and reducing the number of emergency room visits.”

To view the full press release, visit https://ibn.fm/rtowW

About HeartBeam Inc.

HeartBeam is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. By applying a suite of proprietary algorithms to simplify vector electrocardiography (“VECG”), the HeartBeam platform enables patients and their clinicians to determine quickly and easily if symptoms are due to a heart attack so care can be expedited if required. HeartBeam has two patented products in development. HeartBeam AIMI(TM) is software for acute care settings that provides a 3D comparison of baseline and symptomatic 12-lead ECG to more accurately identify a heart attack. HeartBeam AIMIGo is the first and only credit card-sized 12-lead output ECG device coupled with a smart phone app and cloud-based diagnostic software system to facilitate remote heart attack detection. HeartBeam AIMI and AIMIGo have not yet been cleared by the US Food and Drug Administration (“FDA”) for marketing in the United States or other geographies. For more information, visit www.HeartBeam.com.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Mullen Automotive (NASDAQ: MULN) Releases New Info about Upcoming Mullen Five RS

September 28, 2022 11:41:58

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, announced an upcoming version of its Mullen Five crossover that delivers a performance “to rival Plaid versions of Tesla’s Model S and Model X.” The Mullen Five was originally meant to compete against Tesla’s Model Y and Volkswagen ID.4, but the new version features more than 1,000 horsepower and the ability to go from 0 to 60 in under 2 seconds with a top speed of more than 200 mph; the new model also features an 800-volt electrical system, enabling rapid charge times when using a DC fast charger. The FIVE RS will be manufactured in MULN’s Tunica, Mississippi, plant and is expected to be revealed next spring, with the standard version starting at about $55,000. The company anticipates delivering the first vehicles in 2024. “From the inception of Mullen, it has been my mission to bring an ultrahigh-performance EV to market,” said Mullen Automotive CEO and chair David Michery in the press release. “The Five RS is intended to be one of the fastest vehicles on the planet, competing with some of the best and most well-known and regarded automotive marques.”

To view the full article, visit https://ibn.fm/Pmpw5

About Mullen Automotive Inc.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

InMed Pharmaceuticals (NASDAQ: INM) Announces 2022 Financial Results

September 26, 2022 12:23:12

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022. “In the final quarter of our fiscal 2022, as well as throughout the previous fiscal year, we have made important advancements in our pharmaceutical drug development programs, including expanding our phase 2 clinical trial for the treatment of symptoms related to epidermolysis bullosa to include adolescents, and initiating a research collaboration agreement to further screen cannabinoid analogs for potential therapeutic uses. As announced on Sept. 8, 2022, we have made the decision to reduce the efforts of our subsidiary, BayMedica, to pursue commercialization of rare cannabinoids in the health and wellness sector,” said InMed CEO Eric A. Adams. “Moving forward, the company is realigning its focus and resources towards advancing our pharmaceutical drug development programs with the aim of achieving important milestones in the coming quarters and year.”

To view the full press release, visit https://cnw.fm/4rFfu

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. The company also has significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Flora Growth (NASDAQ: FLGC) Expands Global Footprint to Add 3 International Markets

September 26, 2022 12:22:39

Flora (NASDAQ: FLGC) is a leading all-outdoor cultivator, manufacturer and distributor of global cannabis products and brands. The company today announced that it has completed its first exports of Colombian grown high-CBD dried cannabis flower to Switzerland and the Czech Republic as well as CBD isolate to the United States. “As our global distribution network continues to evolve, adding these three industry-leading countries to our footprint is a major milestone for Flora,” said Luis Merchan, chairman and CEO of Flora Growth. “Our cultivation operation in Colombia, which provides high-quality, high-margin flower and derivatives, has experienced increasing demand. These exports are a testament to our team’s ability to execute in a very complex global regulatory environment and create new commercial revenue for our company.”

To view the full press release, visit https://cnw.fm/9Baa1

About Flora Growth Corp.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Cepton (NASDAQ: CPTN) Receives LOI for Up to $100M Investment from Strategic Investor

September 26, 2022 12:22:17

Cepton received a letter of intent from Koito for an investment of up to $100 million to help fund Cepton’s next stage of growth as it scales for mass market deployment
Lidar technology within urban settings is becoming increasingly ubiquitous across automotive (i.e., assisted driving & autonomous vehicles) and smart infrastructure
Since being the recipient of the largest known ADAS contract from an automotive manufacturer within the lidar space, Cepton maintains a major frontrunner

Cepton’s (NASDAQ: CPTN) long-term automotive Tier 1 partner, Koito Manufacturing Co., Ltd. recently revealed that it had provided Cepton with a Letter of Intent representing an investment of up to $100 million to help fund Cepton’s next stage of growth as it seeks to scale its lidar solutions for mass deployment (https://ibn.fm/2nIDH). This investment would bolster Cepton’s balance sheet and allow the company to develop the manufacturing and supply chain capabilities it needs to meet the expected demand from the rapidly expanding lidar market.

Lidar technology has become increasingly ubiquitous, particularly within urban settings. For example, Chinese tech giant Baidu recently revealed that its autonomous vehicle-powered ride-hailing service had successfully processed its one millionth ride, a remarkable feat achieved only twenty-four months post…

NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems Los Angeles, California www.TinyGems.net 310.299.1717 Office [email protected]

TinyGems is part of the InvestorBrandNetwork

Mullen (NASDAQ: MULN) Announces Dates for Strikingly Different Fall Tour

September 26, 2022 12:21:29

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, has released the kickoff dates for its Strikingly Different tour; the fall tour features the Mullen FIVE EV Crossover. The tour begins on Oct. 27–28, 2022, at the Rose Bowl in Pasadena followed by a stop at the Las Vegas Motor Speedway on Nov. 10–11. In addition, the tour will make stops in both Dallas and Houston in November, with December locations slated in Memphis, Miami, Atlanta and Charlotte. The second leg of the tour will begin in spring 2023 with the tour heading to the East Coast as well as Midwest and northwest locations; the tour will wrap up in northern California. The spring stops will spotlight the Mullen FIVE RS, MULN’s high-performance EV sport crossover. The Strikingly Different tour is designed to give participants an up-close look at Mullen’s exclusive electric vehicle offerings. “In keeping true to our commitments, we proudly announce the kickoff of the Strikingly Different tour,” said Mullen Automotive CEO, founder and chair David Michery in the press release. “As our exciting initiatives continue to move at a rapid pace, we will make every effort to provide our shareholders with ongoing updates.”

To view the full press release, visit https://ibn.fm/HDb54

About Mullen Automotive Inc.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Energy Stocks

Green Energy Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the InvestorBrandNetwork (IBN) to millions of social media followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.

To receive SMS text alerts from Green Energy Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.greennrgstocks.com

Please see full terms of use and disclaimers on the Green Energy Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.greennrgstocks.com/Disclaimer

Green Energy Stocks
Los Angeles, CA
greennrgstocks.com
415.949.5050 Office
[email protected]

Green Energy Stocks is part of the InvestorBrandNetwork.

Knightscope (NASDAQ: KSCP) Secures Contract with Global Commercial Real Estate Broker

September 23, 2022

September 23, 2022 12:19:39

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced that one of the largest commercial real estate services companies in the world has reached an agreement to engage Knightscope’s K5 Autonomous Security Robot (“ASR”) patrols for a prominent Chicago skyscraper. According to Knightscope, this is the company’s first contract in Chicago and the state of Illinois.

The announcement reads, “The real estate, renting and leasing industry employs over 2 million people and is one of the largest sectors in the U.S. economy, accounting for over 10% of the country’s GDP. One of its top vulnerabilities is property damage, which affects management’s reputation with office building personnel, tenants and visitors. Commercial property security services must incorporate advanced technologies like Knightscope’s to deliver a more comprehensive solution specifically tailored to the client’s unique needs.”

To view the full press release, visit https://ibn.fm/4b8s7

About Knightscope

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About TinyGems

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.net

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.net
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork

CNS Pharmaceuticals (NASDAQ: CNSP) to Present at Innovations in Oncology Event

September 23, 2022

September 23, 2022 12:19:18

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will present at the following event at 1:00 p.m. ET on Wednesday, Sept. 28, 2022: Virtual Investor Innovations in Oncology – Ongoing Pivotal Global Study for Treatment of Glioblastoma Multiforme (“GBM”). As part of the virtual event, Climaco will discuss the company’s ongoing potentially pivotal global study evaluating its efficacy and safety in the treatment of GBM. Interested parties should visit https://ibn.fm/ktCnW to register for the webinar. A live video webcast of the event will be available on the company’s website, and a webcast replay will be available two hours following the live presentation and accessible for 90 days.

To view the full press release, visit https://ibn.fm/KBYyG

About CNS Pharmaceuticals Inc.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

DoubleDown Interactive (NASDAQ: DDI) Role-Playing Game Celebrates 1st Anniversary

September 22, 2022

September 22, 2022 13:37:44

DoubleDown Interactive (NASDAQ: DDI), a leading gaming company delivering unique player experiences across a variety of genres, is celebrating the first anniversary of Undead World: Hero Survival. The zombie-battler role-playing game has been downloaded by over 1,000,000 players within its first year. “We are proud to celebrate this first-year milestone for Undead World: Hero Survival,” said In Keuk Kim, CEO of DoubleDown. “With regular content updates, a variety of rotating mini-games and in-game events, and an engaging ongoing story, the game has already found a devoted player base. We look forward to growing the audience as we move into year two.”

To view the full press release, visit https://ibn.fm/Y9HGk

About DoubleDown Interactive Co. Ltd.

DoubleDown Interactive is a leading developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players, bringing authentic Vegas entertainment to players around the world through an online social casino experience. Its flagship title, DoubleDown Casino, has been a fan-favorite game on leading social and mobile platforms for years, entertaining millions of players worldwide with a lineup of classic and modern games. For more information, visit www.DoubleDownInteractive.com.

About InvestorWire

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

HeartBeam (NASDAQ: BEAT) Releases New Video Exploring Tech, Progress of AIMIGo(TM)

September 21, 2022 14:22:41

HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere. The company today announced that, in conjunction with its upcoming virtual roadshow webinar taking place at 4:30 p.m. ET on Tuesday, Sept. 20, 2022, it has released a new video that takes viewers behind the scenes for a featured look at the HeartBeam AIMIGo technology. “This new video provides a compelling overview and explanation of our technologies and highlights our continued progress toward making the AIMIGo device available for remote heart attack detection,” said Branislav Vajdic, PhD, HeartBeam CEO and founder. “We look forward to sharing the video at our upcoming webinar along with recent announcements, ongoing initiatives and key 2022 and 2023 milestones.”

To view the full press release, visit https://ibn.fm/x55nd

About HeartBeam Inc.

NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Lexaria Bioscience (NASDAQ: LEXX) Looking to Provide Oral Treatment for Hypertension

September 21, 2022 14:22:07

Lexaria is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”)
The company has developed the patented DehydraTECH(TM) drug delivery technology, which has been shown to deliver more API at a faster rate than controls
Lexaria’s DehydraTECH pipeline includes DehydraTECH-CBD for the treatment of hypertension
Through pre-clinical studies, DehydraTECH-CBD has been shown to decrease systolic blood pressure among hypertensive volunteers
The company intends to file an Investigational New Drug (“IND”) application and has already received confirmation that the FDA agrees with its proposed abbreviated pathway under section 501(b)(2)

Oral delivery remains the preferred route of administering drugs among cooperating and conscious patients. But some drugs do not have the desired physicochemical and pharmacokinetic characteristics that favor oral administration, an issue that is linked to poor bioavailability. This has often led to the use of other routes or prompted the administration of higher doses, with the latter causing toxicity concerns and risks tied to erratic and unpredictable responses. These challenges, coupled with the fact that more than 90% of therapeutic compounds are known to possess oral bioavailability limitations, have necessitated research that explores ways to enhance oral drug bioavailability (https://cnw.fm/5fM38).

The research has been spearheaded by scholars and scientists as well as companies such as Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms. A biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a…

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.

Knightscope (NASDAQ: KSCP) to Take the Spotlight with a Robot in Sterling, Virginia

September 21, 2022 14:21:35

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, has announced that its Robot Roadshow will land at 22895 Ladbrook Drive in Sterling, Virginia, on Sept. 20-21, 2022. The Robot Roadshow is an engaging experiential event designed to grab attention, forge direct connections with potential clients, and strike up conversations in a compelling fashion.

The announcement reads, “The Robot Roadshow has made 56 landings in 22 states and Washington, D.C., to date. Knightscope’s crime-fighting robots tour the U.S. in a space-age, NASA-like ‘pod’ allowing attendees to experience all the technology that is enabling these Autonomous Security Robots (‘ASRs’) to help make sites safer today from Hawaii to Texas to North Carolina.”

To view a short video of a past event hosted by the Los Angeles Police Department, visit https://ibn.fm/n69H9

To view the full press release, visit https://ibn.fm/RqRwy

About Knightscope

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About ESGWireNews

To receive SMS text alerts from ESGWireNews, text “ESG” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.ESGWireNews.com

Please see full terms of use and disclaimers on the ESGWireNews website applicable to all content provided by ESGWireNews, wherever published or re-published: https://www.ESGWireNews.com/Disclaimer

ESGWireNews
Los Angeles, California
www.ESGWireNews.com
310.299.1717 Office
[email protected]

ESGWireNews is part of the InvestorBrandNetwork

Aditxt (NASDAQ: ADTX) Closes on Recently Announced $20M Public Offering

September 21, 2022 14:20:51

Aditxt Inc. (NASDAQ: ADTX), a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system, has closed on its recent public offering. The offering was comprised of 3,333,333 shares of common stock or common stock equivalents; the offering also included warrants to purchase up to 3,333,333 shares of common stock. The combined offering price to the public was $6 per share and associated warrant, with the warrants, which are exercisable upon being issued, having an exercise price of $6 per share. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering, which resulted in approximately $20 million in gross proceeds for the company. Aditxt anticipates using the net proceeds from the offering for working capital and operating expenses.

To view the full press release, visit https://ibn.fm/1D16l

About Aditxt Inc.

Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. The company’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit www.Aditxt.com and www.AditxtScore.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Cybin (NYSE American: CYBN) (NEO: CYBN) to Participate in Upcoming Conferences

September 21, 2022 14:20:29

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated in a panel discussion titled “Trials to Treatments” at the Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, Ethics & Business Event in Haarlem, Amsterdam. The announcement includes further details on additional conferences and the participation schedule for Drysdale and additional members of Cybin’s management team in panel discussions and presentations. The additional events include the Interdisciplinary Conference on Psychedelic Research, Sept. 22-24, 2022, in Haarlem, Amsterdam, Jefferies Innovation in Mental Health Summit, Sept. 22, 2022, in New York City, New York, and the Cantor Neurology & Psychiatry Conference, Oct. 6-7, 2022, in San Francisco, California.

To view the full press release, visit https://ibn.fm/Osgqu

About Cybin Inc.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About BioMedWire

To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Flora Growth (NASDAQ: FLGC) Revenue Growth for H1 2022 Affirms Hyper Growth

September 21, 2022 14:19:41

H1 2022 revenue increased to ~$15.0 million, up 604% from H1 2021 and 117% from H2 2021, driven by House of Brands
Gross Profit increased to ~$7.0 million, up 547% compared to H1 2021 and 363% compared to H2 2021
Company reaffirms its 2022 revenue guidance to range between $35.0 million – $45.0 million, indicating approximately 300% – 400% projected revenue growth from 2021

In August, Flora (NASDAQ: FLGC) released its financial and operating results for the six months that ended June 30, 2022 (https://cnw.fm/4Oeqb). As an internationally focused cannabis company, the organization’s management acknowledged how challenging the current global cannabis environment is. However, it also lauded the team’s ability to deliver on plan and the overall company’s focus on its goals for the current financial year.

The release indicated that Flora posted total revenue of $14.9 million for the first half of the 2022 fiscal year (“H1 2022”), 7x year-over-year (“YOY”) growth, and 2x sequential growth. This growth was attributed to Flora’s House of Brands division, which include the acquisitions of Vessel and…

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
[email protected]

CannabisNewsWire is part of the InvestorBrandNetwork.

Mullen Automotive’s (NASDAQ: MULN) Bollinger Motors Teams Up with Wabash

September 21, 2022 14:19:11

Mullen Automotive (NASDAQ: MULN), through its recent majority acquisition, Bollinger Motors Inc., is partnering with Wabash, a leading truck body and trailer manufacturer. The partnership will focus on developing a stronger, lighter, refrigerated truck body on an electric chassis. The plan is to seamlessly integrate Bollinger’s Class 4 electric chassis cab with Wabash’s lightweight composite technology, EcoNex(TM), which will be used in truck bodies and trailers. According to the announcement, the exclusive EcoNex technology’s composite material is lighter and more durable and thermally efficient than other commercial products. With that in mind, the new offering will feature weight savings because of Wabash’s lightweight EcoNex composite technology, electrification of customer fleets utilizing Bollinger’s all-electric chassis cab, increased total payload capacity, breakthrough improvement in thermal efficiency and overall cost savings. A Wabash representative noted that the all-electric truck will be highly efficient with more uptime and less charging compared to conventional construction. “I’m excited to help ‘green up’ the journey from farm to table,” said Bollinger Motors founder and CEO Robert Bollinger in the press release. “We’re confident Wabash’s expertise in commercial transportation, combined with Bollinger’s leadership in Class 4 electrification, will deliver a superior product for customers looking to reduce their carbon footprints.”

To view the full press release, visit https://ibn.fm/xG6o6

About Mullen Automotive Inc.

Mullen Automotive is a southern California-based automotive company building the next-generation of premium electric vehicles (EVs) that are affordable and built entirely in the United States. With an end-to-end ecosystem that supports owners from test driving to financing and servicing through a unique hybrid dealership model, customers are supported through every aspect of EV ownership. The Mullen FIVE, the company’s first electric crossover, is slated for delivery in 2024 and features an award-winning design and its patented PERSONA technology that utilizes facial recognition to personalize the driving experience for every individual. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About Green Car Stocks

To receive SMS text alerts from Green Car Stocks, text “Green” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.GreenCarStocks.com

Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer

Green Car Stocks
Los Angeles, CA
www.GreenCarStocks.com
415.949.5050 Office
[email protected]

Green Car Stocks is part of the InvestorBrandNetwork.

Cepton (NASDAQ: CPTN) Collaborates to Bridge Gap in Autonomous Driving Tech